T2 Biosystems (TTOO) 10-Q 22 May 23 2023 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2023	May 17, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Trading Symbol	TTOO
Entity Registrant Name	T2 Biosystems, Inc.
Entity Central Index Key	0001492674
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	001-36571
Entity Tax Identification Number	20-4827488
Entity Address, Address Line One	101 Hartwell Avenue
Entity Address, City or Town	Lexington
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02421
City Area Code	781
Local Phone Number	761-4646
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, par value $0.001
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		24,887,722

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 10,117	$ 10,329
Accounts receivable	1,323	2,163
Inventories	4,936	4,285
Prepaid expenses and other current assets	2,549	2,582
Total current assets	18,925	19,359
Property and equipment, net	4,801	4,533
Operating lease right-of-use assets	8,420	8,741
Restricted cash	551	1,551
Other assets	35	143
Total assets	32,732	34,327
Current liabilities:
Accounts payable	3,131	1,296
Accrued expenses and other current liabilities	5,162	7,269
Operating lease liability	1,415	1,352
Warrant liabilities	7,972	39
Deferred revenue	149	172
Total current liabilities	17,829	10,128
Notes payable	50,108	49,651
Operating lease liabilities, net of current portion	7,832	8,214
Deferred revenue, net of current portion	74	52
Derivative liability related to Term Loan	1,858	1,088
Accrued interest on term loan	4,917	4,849
Total liabilities	82,618	73,982
Commitments and contingencies (see Note 13)
Stockholders’ deficit
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 400,000,000 shares authorized; 20,720,315 and 7,716,519 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	21	8
Additional paid-in capital	502,277	494,556
Accumulated deficit	(552,184)	(534,219)
Total stockholders’ deficit	(49,886)	(39,655)
Total liabilities and stockholders' deficit	$ 32,732	$ 34,327

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement Of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	20,368,463	7,716,519
Common stock, shares outstanding	20,368,463	7,716,519

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue:
Total revenue	$ 2,078	$ 7,234
Costs and expenses:
Research and development	4,471	6,656
Selling, general and administrative	7,299	9,230
Total costs and expenses	15,765	22,091
Loss from operations	(13,687)	(14,857)
Other income (expense):
Interest income	2	3
Interest expense	(1,522)	(1,650)
Change in fair value of derivative related to Term Loan	(770)
Change in fair value of warrant liabilities	(1,304)
Other income		11
Other expense	(682)
Other losses	(2)	(2)
Total other expense	(4,278)	(1,638)
Net loss and comprehensive loss	$ (17,965)	$ (16,495)
Net loss per share — basic	$ (1.32)	$ (4.86)
Net loss per share — diluted	$ (1.32)	$ (4.86)
Weighted-average number of common shares used in computing net loss per share — basic	13,633,352	3,397,103
Weighted-average number of common shares used in computing net loss per share — diluted	13,633,352	3,397,103
Product [Member]
Revenue:
Total revenue	$ 1,655	$ 3,844
Costs and expenses:
Cost of product revenue	3,995	6,205
Contribution [Member]
Revenue:
Total revenue	$ 423	$ 3,390

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Deficit - USD ($) $ in Thousands	Total	Secondary Offering [Member]	Common Stock [Member]	Common Stock [Member] Secondary Offering [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] Secondary Offering [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
Balance at Dec. 31, 2021	$ (12,903)		$ 3		$ 459,314		$ (472,216)	$ (4)
Balance (in shares) at Dec. 31, 2021			3,328,017
Stock-based compensation expense	2,552				2,552
Issuance of common stock from vesting of restricted stock (in shares)			40,028
Surrender of shares due to tax withholding	(231)				(231)
Surrender of shares due to tax withholding (in shares)			(10,781)
Issuance of common stock from offering, net		$ 1,433				$ 1,433
Issuance of common stock from offering, net (in shares)				70,981
Unrealized loss on marketable securities	(7)							(7)
Net loss	(16,495)						(16,495)
Balance at Mar. 31, 2022	(25,651)		$ 3		463,068		(488,711)	$ (11)
Balance (in shares) at Mar. 31, 2022			3,428,245
Balance at Dec. 31, 2022	$ (39,655)		$ 8		494,556		(534,219)
Balance (in shares) at Dec. 31, 2022	7,716,519		7,716,519
Stock-based compensation expense	$ 1,833				1,833
Issuance of common stock from vesting of restricted stock (in shares)			67,526
Issuance of common stock from offering, net		$ 930		$ 1		$ 929
Issuance of common stock from offering, net (in shares)				653,122
Issuance of common stock and Pre-Funded Warrant from public offering, net	4,031		$ 9		4,022
Issuance of common stock and Pre-Funded Warrant from public offering, net (in shares)			9,018,519
Issuance of common stock upon Common Stock Warrant cashless exercises	938		$ 1		937
Issuance of common stock upon Common Stock Warrant cashless exercises (in shares)			1,172,037
Issuance of common stock upon Pre-Funded Warrant exercises	2		$ 2
Issuance of common stock upon Pre-Funded Warrant exercises (in shares)			1,740,740
Net loss	(17,965)						(17,965)
Balance at Mar. 31, 2023	$ (49,886)		$ 21		$ 502,277		$ (552,184)
Balance (in shares) at Mar. 31, 2023	20,368,463		20,368,463

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities
Net loss	$ (17,965)	$ (16,495)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	256	286
Non-cash lease expense	321	294
Stock-based compensation expense	1,833	2,552
Change in fair value of derivative related to Term Loan	770
Change in fair value of warrant liabilities	1,304
Issuance costs related to Common Stock Warrants	682
Loss on disposal of property and equipment	3
Non-cash interest expense	526	543
Changes in operating assets and liabilities:
Accounts receivable	840	773
Prepaid expenses and other assets	138	(1,476)
Inventories	(949)	(1,534)
Accounts payable	1,833	553
Accrued expenses and other liabilities	(2,211)	502
Deferred revenue	(1)	(161)
Operating lease liabilities	(320)	(278)
Net cash used in operating activities	(12,940)	(14,441)
Cash flows from investing activities
Purchases and manufacture of property and equipment	(120)	(29)
Net cash provided by investing activities	(120)	(29)
Cash flows from financing activities
Payment of employee restricted stock tax withholdings		(230)
Proceeds from public offering, net of issuance costs	10,918
Proceeds from secondary offering, net of issuance costs	930	1,432
Net cash provided by financing activities	11,848	1,202
Net change in cash, cash equivalents and restricted cash	(1,212)	(13,268)
Cash, cash equivalents and restricted cash at beginning of period	11,880	23,796
Cash, cash equivalents and restricted cash at end of period	10,668	10,528
Supplemental disclosures of cash flow information
Cash paid for interest	1,009	1,106
Supplemental disclosures of noncash activities
Transfer of T2 owned instruments and components (from) to inventory	(298)	(271)
Cashless exercise of Common Stock Warrants	(938)
Purchases of property and equipment included in accounts payable and accrued expenses	$ 136	$ 134

Condensed Consolidated Statem_4

Condensed Consolidated Statement of Cash Flows (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Reconciliation of cash, cash equivalents and restricted cash at end of period
Cash and cash equivalents	$ 10,117	$ 10,329	$ 9,397
Restricted cash	551	1,551	1,131
Total cash, cash equivalents and restricted cash	$ 10,668	$ 11,880	$ 10,528	$ 23,796

Nature of Business

Nature of Business	3 Months Ended
	Mar. 31, 2023
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of Business	1. Nature of Business T2 Biosystems, Inc. and its subsidiary (the “Company,” “we,” or “T2”) have operations based in Lexington, Massachusetts. T2 Biosystems, Inc. was incorporated on April 27, 2006 as a Delaware corporation. The Company is an in vitro diagnostics company that has developed an innovative and proprietary technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company has developed a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. The Company's technology enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (“CFU/mL”). We are currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs. The Company's current development efforts primarily target sepsis and Lyme disease, which are areas of significant unmet medical need in which existing therapies could be more effective with improved diagnostics. Liquidity and Going Concern At March 31, 2023 , the Company had cash, cash equivalents, and restricted cash of $ 10.7 million, an accumulated deficit of $ 552.2 million, stockholders’ deficit of $ 49.9 million and has experienced cash outflows from operating activities since its inception. The future success of the Company is dependent on its ability to successfully commercialize its products, obtain regulatory clearance for and successfully launch its future product candidates, obtain additional capital and ultimately attain profitable operations. Historically, the Company has primarily funded its operations through public equity and private debt financings. In Febru ary 2023, we raised $ 12.0 million through a co mmon stock and warrants sale (Note 7). The Company is subject to a number of risks similar to other early commercial stage life science companies, including, but not limited to commercially launching the Company’s products, development and market acceptance of the Company’s product candidates, development by its competitors of new technological innovations, protection of proprietary technology, and raising additional capital. The Company’s T2Dx Instrument and T2Candida and T2Bacteria Panels are authorized for use in the United States by the Food and Drug Administration, or FDA. In June 2020 the FDA extended Emergency Use Authorization, or EUA, to the Company’s T2SARS-CoV-2 Panel. The Company believes the FDA will rescind the EUA for all COVID-19 diagnostic tests, and has indicated that it will provide a 180 day transition period. The COVID-19 pandemic has impacted and may continue to impact the Company’s operations as the pandemic shifts to an endemic health threat. Customers have begun to reduce their purchases of the Company’s COVID-19 test and the Company has not forecasted any COVID-19 test sales in 2023. The Company has a significant development contract with the Biomedical Advanced Research and Development Authority (“BARDA”) and should BARDA reduce, cancel or not grant additional milestone projects, the Company’s ability to continue its future product development may be hindered. The Company believes that its cash, cash equivalents, and restricted cash of $ 10.7 million at March 31, 2023 will not be sufficient to fund its current operating plan through the second quarter of 2023. Certain elements of the Company's operating plan cannot be considered probable, and in order to support the business, the Company initiated a process to explore a range of strategic alernatives focused on maximizing values. Under ASC 205-40, the future receipt of potential funding from co-development partners and other resources cannot be considered probable at this time because none of the plans are entirely within the Company’s control. As part of a strategic restructuring program, to preserve capital and be in a better position to explore all strategic alternatives while continuing to support customers and advance pipeline development, the Company initiated a reduction in force of nearly 30 % of the workforce on May 19, 2023. Additionally, the Company is focused on pursuing alternative strategic options, including an acquisition, merger, reverse merger, other business combination, sale of assets or licensing. The Company is also exploring additional equity financing and converting our outstanding indebtedness into equity. Failure to secure any of these strategic options prior to the third quarter of 2023 will significantly impair the Company's ability to continue operating its business and the Company may be forced to cease operations, commence bankruptcy cases, or otherwise wind down business. The Term Loan Agreement with CRG Servicing LLC (“CRG”), as administrative agent and collateral agent (the "Term Loan Agreement") (Note 6) has a minimum liquidity covenant which requires the Company to maintain a minimum cash balance of $ 5.0 million. In February 2022, CRG, the lenders party thereto and the Company amended the Term Loan Agreement, extending the interest only period and maturity to December 30, 2023. In November 2022, CRG amended the Term Loan Agreement, extending the interest only period and maturity to December 30, 2024 . On May 15, 2023, the Company notified CRG that it was not in compliance with the minimum liquidity covenant as of May 12, 2023 and on May 19, 2023, the Company, the lenders party thereto and CRG entered into a waiver and consent with respect to the Term Loan Agreement, reducing the minimum liquidity covenant to $ 500,000 until December 31, 2023. The Nasdaq Stock Market LLC (“Nasdaq”) has $ 1.00 minimum bid price and $ 35 million minimum market value rules. Since 2021, the Company has failed to comply with Nasdaq listing requirements but subsequently regained compliance for certain markets. On November 22, 2022, the Company received notice from the Nasdaq indicating that the Company was in violation of the $ 35 million minimum market value rule. The Company has until May 22, 2023, to regain compliance which includes a closing market value of $ 35 million or more for a minimum of ten consecutive business days. If compliance in not achieved by May 22, 2023, the Company believes the Nasdaq will notify the Company that its securities are subject to delisting. In the event the Company receives such a delisting notice, the Company intends to apply to the Nasdaq Hearings Panel for an extension to the compliance period or appeal to a Nasdaq Hearings Panel. On March 30, 2023, the Company received a letter from the Nasdaq indicating that, for the last thirty consecutive business days, the bid price for its common stock had closed below the minimum $ 1.00 per share requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1). Under Nasdaq rules, the Company has 180 calendar days (September 26, 2023) to regain compliance by increasing the stock price to over $ 1.00 . Absent significant appreciation in the Company’s stock price, the Company plans to submit an appeal to receive a 180 -day extension to regain compliance, and believes that the receipt of an extension is probable, given the current market dynamics and hundreds of companies in similar situations. To earn the extension, the Company will likely be required to provide a plan that could include certain commitments including a potential reverse stock split. These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date that the financial statements are issued. Management's plans to alleviate the conditions that raise substantial doubt include raising additional funding, earning payments pursuant to the Company’s contract with BARDA, delaying certain research projects and capital expenditures and eliminating certain future operating expenses in order to fund operations at reduced levels for the Company to continue as a going concern for a period of 12 months from the date these condensed consolidated financial statements are issued. Management has concluded the likelihood that its plan to successfully obtain sufficient funding from one or more of these sources or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about the Company’s ability to continue as a going concern for a period of at least 12 months from the date of issuance of these financial statements. Even if we are able to complete the actions described in this paragraph or otherwise generate incremental liquidity, we may be forced to sell material assets or seek additional capital or be required to commence proceedings under Chapter 11 of the U.S. Bankruptcy Code. See Part II, Item 1A—“Risk Factors” in this Quarterly Report on Form 10-Q. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The Company’s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). The Company’s condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, T2 Biosystems Securities Corporation. All intercompany balances and transactions have been eliminated. On October 12, 2022, we effected a 50 for 1 reverse stock split. One share of common stock was issued for every 50 shares of issued and outstanding , fractional shares were settled in cash and adjustment made for 50 shares of rounding. A ll references to share and per share amounts (excluding authorized shares) in the condensed consolidated financial statements and accompanying notes have been retroactively restated to for the reverse split. Unaudited Interim Financial Information Certain information and footnote disclosures normally included in the Company’s annual financial statements have been condensed or omitted. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The accompanying interim condensed consolidated balance sheet as of March 31, 2023, the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2023 and 2022, the condensed consolidated statements of stockholders’ deficit for the three months ended March 31, 2023 and 2022, the condensed consolidated statements of cash flows for the three months ended March 31, 2023 and 2022 and the related financial data and other information disclosed in these notes are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual financial statements, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of March 31, 2023, and the results of its operations for the three months ended March 31, 2023 and 2022 and its cash flows for the three months ended March 31, 2023 and 2022. The results for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 , any other interim periods, or any future year or period. Reclassification Certain prior year amounts have been reclassified to conform to the current year presentation. Such reclassifications had no impact on the Company's reported total revenues, expenses, net loss, current assets, total assets, current liabilities, total liabilities, stockholders' equity (deficit) or cash flows. No reclassifications of prior period balances were material to the consolidated financial statements. Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision‑making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is the Chief Executive Officer. The Company views its operations and manages its business in one operating segment, which is the business of developing and, upon regulatory clearance, launching commercially its diagnostic products aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. Going Concern Pursuant to the requirements of Accounting Standards Codification 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern ("ASC 205-40"), management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. Geographic Information The Company sells its products domestically and internationally. Total international sales were approximately $ 0.8 million or 36 % of total revenue and $ 1.0 million or 13 % of total revenue for the three months ended March 31, 2023 and 2022, respectively. International sales to Italy was $ 0.4 million or 19 % of total revenue for the three months ended March 31, 2023. International sales to any customer in a single country did not exceed 10 % of total revenue for the three months ended March 31, 2022. The following table shows customers that represent greater than 10% of total revenue for the period presented: Three Months Ended 2023 2022 Customer A 20 % 47 % Customer B 19 % 5 % Customer A is a U.S. government customer (BARDA). Customer B is an international distributor. The following table shows customers that represent greater than 10% of the accounts receivable balance for the period presented: March 31, December 31, Customer A — % 32 % Customer B 28 % — % Customer A is a U.S. government customer (BARDA). Customer B is an international distributor. As of March 31, 2023 and December 31, 2022, the Company had outstanding receivables of $ 1.4 million and $ 0.4 million, respectively, from customers located outside of the U.S. Net Loss Per Share The Company has issued certain securities that are participating securities; therefore, the Company must apply the two-class method to determine basic and diluted earnings per share. To the extent that a dividend or distribution is declared or paid during the period, the Company applies the two-class method to determine the allocation of the dividends or distributions between the common shareholders and the holders of the participating securities. The Company’s participating securities do not have an obligation to share in the losses of the Company. To the extent that the Company remains in a net loss position, the two-class method will not apply since the entire net loss would be allocated to the common shareholders. Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period and potential common shares exercisable for little to no consideration, without consideration for other common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding and potential common shares exercisable for little to no consideration used to compute basic earnings per share for the dilutive effect of other common stock equivalents that were outstanding during the period, determined using either the if-converted method or the treasury-stock method. Derivative Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives requiring bifurcation in accordance with ASC Topic 815, Derivatives and Hedging . Derivative instruments are measured at fair value at issuance and at each reporting date in accordance with ASC 820 with changes in fair value recognized in the period of change in the condensed consolidated statements of operations and comprehensive loss. The Company determined that both the warrant issued in conjunction with the Series A redeemable convertible preferred stock in August of 2022 and the Common Stock Warrants issued in February 2023 are derivative instruments. The warrant liabilities are classified on the condensed consolidated balance sheets as current because settlement of the warrant liability could be required by the holder within 12 months of the balance sheet date. Changes in fair value are recognized in change in fair value of warrant liabilities in the period of change in the condensed consolidated statements of operations and comprehensive loss. See Notes 3 and 7. The Company has identified a single compound derivative liability related to its Term Loan Agreement with CRG, that is classified as non-current on the condensed consolidated balance sheets to match the classification of the related Term Loan Agreement. Changes in fair value are recognized in change in fair value of derivative related to Term Loan in the period of change in the condensed consolidated statements of operations and comprehensive loss. See Note 6. The Company does not designate its derivative instruments as hedging instruments. Guarantees As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while each such officer or director is, or was, serving at the Company’s request in such capacity. The term of the indemnification is the officer’s or director’s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors’ and officers’ liability insurance coverage that limits its exposure and enables the Company to recover a portion of any future amounts paid. The Company leases office, laboratory and manufacturing space under noncancelable operating leases. The Company has standard indemnification arrangements under the leases that require it to indemnify the landlords against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation or nonperformance of any covenant or condition of the Company’s leases. See Note 13 for a discussion about the Billerica, Massachusetts lease. In the ordinary course of business, the Company enters into indemnification agreements with certain suppliers and business partners where the Company has certain indemnification obligations limited to the costs, expenses, fines, suits, claims, demands, liabilities and actions directly resulting from the Company’s gross negligence or willful misconduct, and in certain instances, breaches, violations or nonperformance of covenants or conditions under the agreements. As of March 31, 2023 and December 31, 2022 , the Company had not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established. Leases Lessee Pursuant to ASC Topic 842, Leases (“ASC 842”), at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less. The exercise of lease renewal options is at the Company's discretion and the periods subject to renewal option are not included in the measurement of the Company’s right-of-use assets and lease liabilities as the renewal options are not reasonably certain of exercise. The Company will continue to evaluate the renewal options and when they are reasonably certain of exercise, the Company will include the renewal period in its lease term. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to the right-of-use asset may be required for items such as prepaid or accrued lease payments. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. In accordance with the guidance in ASC 842, components of a lease should be split into three categories: lease components (e.g. land, building, etc.), non-lease components (e.g. common area maintenance, consumables, etc.), and non-components (e.g. property taxes, insurance, etc.). Then the fixed and in-substance fixed contract consideration (including any related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. The Company made the policy election to not separate lease and associated non-lease components. Each lease component and the related non-lease components are accounted for together as a single component. Lessor The Company derives revenue from leasing its T2-owned instruments through reagent rental agreements (see the Revenue Recognition section below). Customers typically have the right to cancel every twelve months but subject to penalty. As a result of the penalty, the customers are deemed reasonably certain of not exercising their termination rights resulting in a lease term of generally three years. These lease agreements impose no requirement on the customer to purchase the instrument, and the instrument is not transferred to the customer at the end of the lease term. The short-term nature of the lease agreements does not result in lease payments accumulating to an amount that exceeds substantially all of the fair value of the instrument nor is the lease term for the majority of the remaining economic life of the instrument. Instrument leases are generally classified as operating leases as they do not meet any of the sales-type lease or direct financing lease criteria per ASC 842 and are recognized ratably over the duration of the lease. In accordance with these contracts, customers only make payments when consumables are ordered and delivered thus making these payments variable by nature. The Company estimates the expected volume of consumables to be purchased by each customer over the lease term to measure and recognize rental and consumables revenue. Generally, lease arrangements include both lease and non-lease components. The lease component relates to the customer’s right-to-use the T2-owned instrument over the lease term. The non-lease components relate to (1) consumables and (2) maintenance services. Because the timing and pattern of transfer for the operating lease component, the T2-owned instrument, and maintenance components of a reagent rental agreement are recognized over the same time period and in the same pattern, the Company elected the practical expedient to aggregate non-lease components with the associated lease component and account for the combined component as an operating lease for all instrument leases. In the evaluation of whether the lease component (T2-owned instrument) or the non-lease component associated with the lease component (maintenance) is the predominant component, the Company determined that the lease component is predominant as we believe the customer would ascribe more value to the use of the T2-owned instrument than that of the maintenance services. The T2-owned instrument lease and maintenance service performance obligations are classified as a single category of instrument rental revenue within product revenue in the condensed consolidated statements of operations and comprehensive loss (see disaggregated revenue table below in Revenue Recognition section). The consumables non-lease component does not meet the requirements to elect the practical expedient and thus must apply ASC Topic 606, Revenue from Contracts with Customers , as described below in the Revenue Recognition section. The Company considers the economic life of its T2-owned instruments to be five years. The Company believes five years is representative of the period during which the instrument is expected to be economically usable by one or more users, with normal service, for the purpose for which it is intended. The residual value is estimated to be the value at the end of the lease term based on the anticipated fair market value of the units. The Company mitigates residual value risk of its leased instrument by performing regular management and maintenance, as necessary. Revenue Recognition The Company generates revenue from the sale of instruments, consumable diagnostic tests, related services, reagent rental agreements and government contributions. For arrangements in the scope of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”), the Company determines revenue recognition through the following steps: • Identification of a contract with a customer • Identification of the performance obligations in the contract • Determination of the transaction price • Allocation of the transaction price to the performance obligations • Recognition of revenue as a performance obligation is satisfied The amount of revenue recognized reflects the consideration the Company expects to be entitled to receive in exchange for these goods and services. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. Generally, the Company's performance obligations are transferred to customers either at a point in time, typically upon shipment, or over time, as services are performed. Most of the Company’s contracts with distributors in geographic regions outside the United States contain only a single performance obligation, whereas most of the Company’s contracts with direct sales customers in the United States contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately if they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. Excluded from the transaction price are sales tax and other similar taxes which are presented on a net basis. Product revenue is generated by the sale of instruments and consumable diagnostic tests predominantly through the Company’s direct sales force in the United States and distributors in geographic regions outside the United States. The Company generally does not offer product returns or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including its distributors. Payment terms granted to distributors are the same as those granted to end-user customers and payments are not dependent upon the distributors’ receipt of payment from their end-user customers. The Company either sells instruments to customers and international distributors, or retains title and places the instrument at the customer site pursuant to a reagent rental agreement. When an instrument is purchased by a customer or international distributor, the Company recognizes revenue when the related performance obligation is satisfied (i.e. when the control of an instrument has passed to the customer; typically, at shipping point). When the instrument is placed under a reagent rental agreement, the Company’s customers generally agree to fixed term agreements, which can be extended, and incremental charges on each consumable diagnostic test purchased. Revenue from the sale of consumable diagnostic tests (under a reagent rental agreement) is generally recognized upon shipment. The transaction price from consumables purchases is allocated between the lease and nonlease components when related performance obligations are satisfied, as a component of lease and product revenue, and is included as Instrument Rentals in the below table. Revenue associated with reagent rental consumables purchases is currently classified as variable consideration and constrained until a purchase order is received and related performance obligations have been satisfied. Revenue from the sale of consumable diagnostic tests (under instrument purchase agreements) is recognized when control has passed to the customer, typically at shipping point. Shipping and handling costs billed to customers in connection with a product sale are recorded as a component of the transaction price and allocated to product revenue in the condensed consolidated statements of operations and comprehensive loss as they are incurred by the Company in fulfilling its performance obligations. Direct sales of instruments include warranty, maintenance and technical support services typically for one year following the installation of the purchased instrument (“Maintenance Services”). Maintenance Services are separate performance obligations as they are service based warranties and are recognized on a straight-line basis over the service delivery period. After the completion of the initial Maintenance Services period, customers have the option to renew or extend the Maintenance Services typically for additional one year periods in exchange for additional consideration. The extended Maintenance Services are also service based warranties that represent separate purchasing decisions. The Company recognizes revenue allocated to the extended Maintenance Services performance obligation on a straight-line basis over the service delivery period. Fees paid to member-owned group purchasing organizations (“GPOs”) are deducted from related product revenues. The Company warrants that consumable diagnostic tests will be free from defects, when handled according to product specifications, for the stated life of the product. To fulfill valid warranty claims, the Company provides replacement product free of charge. Warranty expense is recognized based on the estimated defect rates of the consumable diagnostic tests. Contribution Revenue The government contract with BARDA is considered a government grant and not considered a contract with a customer and thus not subject to ASC 606. Revenue under the government BARDA contract is earned under a cost-sharing arrangement in which the Company is reimbursed for direct costs incurred plus allowable indirect costs. The government contract revenue is recognized as the related reimbursable expenses are incurred. The cost reimbursement that is reported as revenue is presented gross of the related reimbursable expenses in the Company’s condensed consolidated statements of operations and comprehensive loss; the related reimbursable expenses are expensed as incurred as research and development expense. The Company accounts for these contracts as a government grant by analogy to International Accounting Standards 20 (“IAS 20”), Accounting for Government Grants and Disclosure of Government Assistance. The Company has a significant development contract with BARDA and should BARDA reduce, cancel or not grant additional milestone projects, the Company’s ability to continue future product development may be adversely impacted. Refer to Note 11 for further details regarding the development contract with BARDA. Disaggregation of Revenue The Company disaggregates revenue from contracts with customers by type of products and services, as it best depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. The following table disaggregates our revenue by major source (in thousands): Three Months Ended, 2023 2022 Product revenue Instruments $ 322 $ 646 Consumables 1,177 2,950 Instrument rentals 55 18 Service 101 230 Total product revenue 1,655 3,844 Contribution revenue 423 3,390 Total revenue $ 2,078 $ 7,234 Remaining Performance Obligations Under ASC 606, the Company is required to disclose the aggregate amount of the transaction price that is allocated to unsatisfied or partially satisfied performance obligations as of March 31, 2023. However, the guidance provides certain practical expedients that limit this requirement, and therefore, the Company has elected to not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. The nature of the excluded unsatisfied performance obligations pursuant to the practical expedient include consumable shipments, service contracts, warranties and installation services that will be performed within one year . The amount of the transaction price that is allocated to unsatisfied or partially satisfied performance obligations, that has not yet been recognized as revenue and that does not meet the elected practical expedient is $ 0.2 million as of March 31, 2023. The Company expects to recognize 53 % of this amount as revenue within one year and the remainder within three years . Judgments Certain contracts with customers include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment. Once the performance obligations are determined, the Company determines the transaction price, which includes estimating the amount of variable consideration, based on the most likely amount, to be included in the transaction price, if any. The Company then allocates the transaction price to each performance obligation in the contract based on a relative standalone selling price method. The corresponding revenue is recognized as the related performance obligations are satisfied as discussed in the revenue categories above. Judgment is required to determine the standalone selling price for each distinct performance obligation. The Company determines standalone selling price based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as a range of selling prices, market conditions and the expected costs and margin related to the performance obligations. Contract Assets and Liabilities At March 31, 2023 and December 31, 2022, the Company recorded $ 0.2 million and $ 0.1 million, respectively, of contract assets within other assets on the balance sheet. The contract assets represent revenue recognized for performance obligations in advance of invoicing at the contract level based on the transaction price allocated to the respective performance obligations. The Company’s contract liabilities consist of upfront payments for research and development contracts and maintenance services on instrument sales. Contract liabilities are classified in deferred revenue as current or non-current based on the timing of when revenue is expected to be recognized. At March 31, 2023 and December 31, 2022, the Company had contract liabilities of $ 0.2 million and $ 0.2 million, respectively. Revenue recognized during the three months ended March 31, 2023 relating to contract liabilities at December 31, 2022 was $ 0.1 million and related to straight-line revenue recognition associated with maintenance agreements. Cost of Product Revenue Cost of product revenue includes the cost of materials, direct labor and manufacturing overhead costs used in the manufacture of consumable diagnostic tests sold to customers, related warranty and license and royalty fees. Cost of product revenue also includes depreciation on T2-owned revenue generating T2Dx instruments that have been placed with customers under reagent rental agreements; costs of materials, direct labor and manufacturing overhead costs on the T2Dx instruments sold to customers; and other costs such as customer support costs, royalties and license fees, warranty and repair and maintenance expense on the T2Dx instruments that have been placed with customers under reagent rental agreements. Research and Development Costs Costs incurred in the research and development of the Company’s product candidates are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including activities associated with delivering products or services associated with contribution revenue, clinical trials to evaluate the clinical utility of product candidates, and costs associated with the enhancements of developed products. These costs include salaries and benefits, stock compensation, research related facility and overhead costs, laboratory supplies, equipment, depreciation on T2Dx instruments used for research and development activities and contract services. Selling, General and Administrative Expenses Selling, general and administrative expenses consist primarily of costs for our sales and marketing, finance, legal, human resources, business development and general management functions, as well as professional services, such as legal, consulting and accounting services. Other selling, general and administrative expenses include commercial support activity, facility-related costs, fees and expenses associated with obtaining and maintaining patents, clinical and economic studies and publications, marketing expenses, and travel expenses. We expense the majority of selling, general and administrative expenses as incurred. Recent Accounting Standards From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. Accounting Standards Adopted On September 29, 2022, the FASB issued ASU 2022-04, Liabilities-Supplier Finance Programs (Subtopic 405-50) Disclosure of Supplier Finance Program Obligations. This ASU requires that a buyer in a supplier finance program disclose additional information about the program to allow financial statement users to better understand the effect of the programs on an entity's working capital, liquidity, and cash flows. This update is effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the amendment on roll forward information, which is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted. The Company adopted ASU 2022-04 on January 1, 2023. The adoption did not have a material impact on the Company's financial statements.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. Fair Value Measurements The Company measures the following financial assets at fair value on a recurring basis. There were no transfers between levels of the fair value hierarchy during any of the periods presented. The following tables set forth the Company’s financial assets and liabilities carried at fair value categorized using the lowest level of input applicable to each financial instrument as of March 31, 2023 and December 31, 2022 (in thousands): Balance at Quoted Prices Significant Significant Liabilities: Warrant liabilities $ 7,972 $ — $ 16 $ 7,956 Derivative liability related to Term Loan 1,858 — — 1,858 $ 9,830 $ — $ 16 $ 9,814 Balance at Quoted Prices Significant Significant Liabilities Warrant liabilities $ 39 $ — $ 39 $ — Derivative liability related to Term Loan 1,088 — — 1,088 $ 1,127 $ — $ 39 $ 1,088 The Company maintains money market accounts classified as restricted cash, which are Level 1 assets, for $ 0.6 million at March 31, 2023 and December 31, 2022 (Note 4). The Company estimated the fair value of the warrant issued in conjunction with the Series A redeemable convertible preferred stock in August of 2022 (the "Series A Warrant") (Note 7) using the Black-Scholes Model, which uses multiple inputs including the Company’s stock price, the exercise price of the warrant, volatility of the Company’s stock price, the risk-free interest rate and the expected term of the warrant. The estimated fair value of the Series A Warrant at March 31, 2023 was determined using the following assumptions: Risk-free interest rate 3.61 % Expected dividend yield 0.00 % Expected volatility 120.00 % Expected term 4.88 The Company estimated the fair value of the Common Stock Warrant issued in February of 2023 (the “Common Stock Warrant”) (Note 7) u sing both the Black-Scholes Model and Monte Carlo simulation methods to model different potential settlement outcomes. These models use multiple inputs including the Company’s stock price, the exercise price of the warrant, volatility of the Company’s stock price, the risk-free interest rate and the expected term of the warrant. Such inputs may vary depending on the model applied and the underlying scenario assumptions. Key inputs included the warrant exercise price of $ 1.08 per share, a risk-free interest rate of 3.61 %, expected volatility ranging from 117 % to 119 %, an expected dividend yield of 0.00 %, a stock price of $ 0.54 (adjusted to reflect volume weighting) and an expected term ranging from zero years to 4.88 years, depending on the simulation. The following table provides a roll-forward of the fair value of the Common Stock Warrants (in thousands): Balance at December 31, 2022 $ — Issuance of Common Stock Warrant 7,568 Settlement due to cashless exercise ( 938 ) Change in fair value 1,326 Balance at March 31, 2023 $ 7,956 The Company has a single compound derivative instrument related to its Term Loan Agreement (Note 6) that requires the Company to pay additional interest of 4 % per annum upon an event of default or if any obligation other than the unpaid principal amount of the Term Loan is not paid when due. Fair value is determined quarterly. The fair value at March 31, 2023 and December 31, 2022 is $ 1.9 million and $ 1.1 million, respectively, and is classified as a non-current liability on the balance sheet at March 31, 2023 and December 31, 2022 to match the classification of the related Term Loan Agreement (Note 6). The estimated fair value of the derivative at March 31, 2023 was determined using a probability-weighted discounted cash flow model that includes contingent interest payments under the following scenarios: Probability 4 % contingent interest beginning in Q3 2023 60 % The following table provides a roll-forward of the fair value of the derivative liability related to the Term Loan (in thousands): Balance at December 31, 2022 $ 1,088 Change in fair value of derivative related to Term Loan 770 Balance at March 31, 2023 $ 1,858 The Company is required to disclose the fair value and the level within the fair value hierarchy for financial instruments that are not measured at fair value on a recurring basis. For certain financial instruments, including accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses, the carrying amounts approximate their fair values as of March 31, 2023 and December 31, 2022 because of their short-term nature. Cash and cash equivalents were classified as Level 1 and all other financial instruments were classified as Level 2 within the fair value hierarchy. The Company used Level 3 inputs to measure the fair value of its Term Loan Agreement. Based on these measurements, the Company concluded that the carrying value of the Term Loan Agreement approximates its fair value at March 31, 2023.

Restricted Cash

Restricted Cash	3 Months Ended
	Mar. 31, 2023
Restricted Cash [Abstract]
Restricted Cash	4. Restricted Cash The Company is required to maintain security deposits for its office lease agreements. At December 31, 2022, the Company had lease security deposits, invested in money market accounts, aggregating $ 1.6 million. In January 2023 one of these deposits of $ 1.0 million was claimed by a landlord as compensation for a lease dispute (see Note 13). The remaining collateral deposits aggregating $ 0.6 million at March 31, 2023 were held at Silicon Valley Bank, which was taken over by the FDIC in March 2023. The Company’s full exposure was ultimately covered by the FDIC and no loss was incurred.

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	3 Months Ended
	Mar. 31, 2023
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Supplemental Balance Sheet Information	5. Supplemental Balance Sheet Information Inventories Inventories are stated at the lower of cost or net realizable value on a first-in, first-out basis and are comprised of the following (in thousands): March 31, December 31, Raw materials $ 2,571 $ 2,004 Work-in-process 1,674 1,176 Finished goods 691 1,105 Total inventories, net $ 4,936 $ 4,285 Property and Equipment Property and equipment consist of the following (in thousands): March 31, December 31, Office and computer equipment $ 757 $ 757 Software 783 783 Laboratory equipment 5,594 5,570 Furniture 210 197 Manufacturing equipment 1,454 1,454 Manufacturing tooling and molds 494 494 T2-owned instruments and components 4,285 4,052 Leased T2-owned instruments 1,011 1,014 Leasehold improvements 3,785 3,784 Construction in progress 869 685 19,242 18,790 Less accumulated depreciation and amortization ( 14,441 ) ( 14,257 ) Property and equipment, net $ 4,801 $ 4,533 Construction in progress is primarily comprised of equipment that has not been placed in service. T2-owned instruments and components is comprised of raw materials and work-in-process inventory that are expected to be used or used to produce T2-owned instrument and completed instruments that will be used for internal research and development, clinical studies and reagent rental agreement with customers. At March 31, 2023 and December 31, 2022, there were $ 1.0 million and $ 0.8 million of T2-owned instrument raw materials and work-in-process, respectively. Depreciation expense, a component of cost of product revenue, from instruments under the T2-owned reagent rental pool was immaterial for the three months ended March 31, 2023 and 2022. Total depreciation expense for T2-owned instruments used for internal research and development and clinical studies is recorded as a component of research and development expense. Depreciation and amortization expense of $ 0.3 million was charged to operations for the three months ended March 31, 2023 and 2022. . Accrued Expenses Accrued expenses consist of the following (in thousands): March 31, December 31, Accrued payroll and compensation $ 2,270 $ 2,930 Accrued clinical trial and development expenses 826 1,097 Accrued professional services 604 1,626 Accrued interest 996 1,009 Other accrued expenses 466 607 Total accrued expenses and other current liabilities $ 5,162 $ 7,269 Accrued professional services at December 31, 2022 includes a $ 1.0 million estimated liability related to the Billerica, Massachusetts lease (Note 13).

Notes Payable

Notes Payable	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Notes Payable	6. Notes Payable Future principal payments on the notes payable are as follows (in thousands): March 31, December 31, Term Loan Agreement including PIK interest, before unamortized discount and issuance costs $ 53,453 $ 53,453 Less: unaccrued paid-in-kind interest ( 3,211 ) ( 3,647 ) Less: unamortized discount and deferred issuance costs ( 134 ) ( 155 ) Total notes payable $ 50,108 $ 49,651 The Term Loan Agreement with CRG is classified as non-current at March 31, 2023 and at December 31, 2022, as the Company amended the agreement in November 2022, extended the interest only period and maturity to December 30, 2024 . The warrants to purchase a total of 21,944 shares of the Company's common stock remain outstanding at March 31, 2023. The Term Loan Agreement includes a subjective acceleration clause whereby an event of default, including a material adverse change in the business, operations, or conditions (financial or otherwise), could result in the acceleration of the obligations under the Term Loan Agreement. Also, at CRG's discretion, a default interest rate of an additional 4.0 % per annum may apply during the occurrence and continuance of an event of default. In January 2023, CRG waived certain specified events of default associated with the Company's issuance of shares of Series A convertible preferred stock in August 2022 and the subsequent redemption. There were no other covenant violations during the three-month period ended March 31, 2023. Term Loan Agreement In December 2016, the Company entered into a Term Loan Agreement with CRG and borrowed $ 40.0 million. The Agreement initially had a six-year term, and provided for quarterly interest-only payments through December 30, 2020 and quarterly principal and interest payments thereafter through maturity. The Company issued warrants to CRG to purchase a total of 10,579 shares of the Company’s common stock, exercisable any time prior to December 30, 2026 at a price of $ 77.50 per share. The Agreement has been subsequently amended as described below. Interest on borrowings, as amended, accrue at 11.50 % per year, 8 % of which is payable in cash quarterly and 3.5 % of which is deferred and added to principal until maturity. The Company paid CRG a financing fee based on the loan principal amount drawn and the fee is being amortized over the loan term as debt discount interest expense. A final fee payment of 10 % (initially 8 %, then amended) is due at maturity based on the principal outstanding at maturity. The final fee is accrued as interest expense and recorded as a non-current liability consistent with the classification of the associated debt. In connection with a 2019 amendment of the Term Loan Agreement, the Company issued to CRG warrants to purchase 11,365 shares of the Company’s common stock (“New Warrants”) exercisable any time prior to September 9, 2029 at an exercise price of $ 77.50 per share. The Company may prepay principal at any time partially or in full without prepayment penalty. Borrowings are collateralized by a lien on substantially all Company assets, including intellectual property. The Term Loan Agreement provides for affirmative and negative covenants including a requirement to maintain a minimum cash balance of $ 5.0 million. The Term Loan Agreement includes a subjective acceleration clause whereby an event of default, including a material adverse change in the business, operations, or conditions (financial or otherwise), could result at CRG’s discretion in the acceleration of the obligations under the Term Loan Agreement. Also at CRG’s discretion, a default interest rate of an additional 4.0 % per annum may apply during the occurrence and continuance of an event of default. In January 2023, CRG waived certain specified events of default associated with the Company's issuance of shares of Series A convertible preferred stock in August 2022 and the subsequent redemption. Amendments In 2019, the Term Loan Agreement was amended to reduce minimum revenue targets, extend the interest-only period, extend the principal repayment period and to increase the final payment fee from 8 % to 10 %. The Company issued the New Warrants to CRG, with provisions for termination upon a change of control or a sale of all or substantially all of the assets of the Company. The Company also reduced the exercise price for the warrants previously issued to CRG to purchase an aggregate of 10,579 shares of the Company’s common stock to $ 77.50 . The New Warrants are exercisable any time prior to September 9, 2029, and all of the previously issued warrants are exercisable any time prior to December 30, 2026. In January 2021, the Term Loan Agreement was amended to extend the interest-only payment period until December 30, 2022, extend the initial principal repayment until December 30, 2022, and to reduce the minimum product revenue target for the twenty-four month period beginning on January 1, 2020. The Company did not pay or provide any consideration in exchange for this amendment. The Company accounted for the January 2021 amendment as a modification to the Term Loan Agreement. In June 2021, the Company satisfied the remaining revenue covenant. In February 2022, the Term Loan Agreement was amended to extend the interest-only and the principal maturity dates to December 30, 2023 . The Company did not pay or provide any consideration in exchange for this amendment. As the effective borrowing rate under the amended agreement is less than the effective borrowing rate under the previous agreement, a concession was deemed granted as per ASC Topic 470-60, Debt: Troubled Debt Restructurings by Debtors ("ASC 470-60), and the amendment was accounted for as a troubled debt restructuring. The future undiscounted cash outflows required under the amended agreement exceed the carrying value of the debt immediately prior to the amendment and the amendment did not result in a gain on restructuring. In November 2022, CRG amended the Term Loan Agreement, extending the interest only period and principal maturity to December 30, 2024 . No consideration was given in exchange for the amendment. There were no costs paid to the lender or third parties in association with the amendment. Because a concession was granted, the agreement was accounted for as a troubled debt restructuring under ASC 470-60. The future undiscounted cash outflows required under the amended agreement exceed the carrying value of the debt immediately prior to the amendment and the amendment did not result in a gain on restructuring. On May 19, 2023, the Company, the lenders party thereto and CRG entered into a waiver and consent with respect to the Term Loan Agreement, reducing the minimum liquidity covenant to $ 500,000 until December 31, 2023 .

Warrants

Warrants	3 Months Ended
	Mar. 31, 2023
Warrants And Rights Note Disclosure [Abstract]
Warrants	7. Warrants Series A Warrant On August 15, 2022, the Company issued an aggregate of 3,000 shares of Series A Redeemable Convertible Preferred Stock with a par value of $ 0.001 per share and the Series A Warrant to purchase up to an aggregate of 42,857 shares of common stock of the Company at an exercise price of $ 7.50 per share (such number of shares and exercise price are adjusted for the reverse stock split described in Note 2) for an aggregate subscription amount equal to $ 0.3 million, before deducting estimated offering expenses payable by the Company. In the fourth quarter of 2022, the Series A Redeemable Convertible Preferred Stock was redeemed. The Series A Warrant became exercisable on February 15, 2023 and expires on February 15, 2028 . The Series A Warrant contains certain anti-dilution provisions to protect the holder. On February 17, 2023, the Company issued and sold shares of common stock, pre-funded warrants to purchase common stock and warrants to purchase common stock to an underwriter pursuant to an underwriting agreement (see discussion below). The terms of that offering triggered an adjustment to the exercise price of the Series A Warrant to $ 0.54 effective as of February 17, 2023. The Company is required to measure the Series A Warrant at fair value at inception and in subsequent reporting periods with changes in fair value recognized in change in fair value of warrant liabilities in the period of change in the condensed consolidated statements of operations and comprehensive loss. The fair value of the liability related to the Series A Warrant at inception was $ 0.4 million. The Series A Warrant was not exercised as of March 31, 2023 and remains outstanding. The change in fair value during the three-month period ended March 31, 2023 was a gain of less than $ 0.1 million. Pre-Funded Warrants and Common Stock Warrants On February 17, 2023, the Company sold 9,018,519 shares of $ 0.001 par value common stock, 2,092,592 Pre-Funded Warrants and 22,222,222 Common Stock Warrants through an offering underwritten by Craig-Hallum Capital Group LLC. Each of the shares and Pre-Funded Warrants were sold in combination with an accompanying Common Stock Warrant to purchase two shares of the Company's common stock. The combined purchase price for each share and accompanying Common Stock Warrant is $ 1.08 , and for each Pre-Funded Warrant and accompanying Common Stock Warrant is $ 1.079 , which was equal to the combined purchase price for each share and accompanying Common Stock Warrant sold in the offering, minus the Pre-Funded Warrant’s exercise price per share of $ 0.001 . The total proceeds of $ 12.0 million from the February 17, 2023 offering were allocated between the common stock, Pre-Funded Warrants and Common Stock Warrants. Because the Common Stock Warrants are liability-classified, an amount of proceeds equal to the fair value of the liability were first allocated to the Common Stock Warrants. The remaining proceeds were allocated on a relative fair value basis to the common stock and the Pre-Funded Warrants and recognized in additional paid-in capital. Total issuance costs related to the offering of $ 1.1 million were allocated in a similar manner as the total proceeds. As a result, approximately $ 0.7 million of issuance costs were expensed at the issuance date and recognized as other expenses in the condensed consolidated statements of operations and comprehensive loss. The remaining issuance costs were recognized within additional paid-in-capital as a reduction to the proceeds received for the common stock and Pre-Funded Warrants. The Pre-Funded Warrants have (i) an exercise price per share of Common Stock equal to $ 0.001 or (ii) a cashless exercise option, with the number of shares received determined according to the formula set forth in the Pre-Funded Warrant. The Pre-Funded Warrants are exercisable upon issuance and do not expire. The exercise price and the number of shares of common stock issuable upon exercise of the Pre-Funded Warrants is subject to adjustment in the event of certain stock dividends and distributions, splits, combinations, reclassifications or similar events affecting the common stock. Holders of Pre-Funded Warrants will participate in any distributions to common stockholders as if the holders had exercised the Pre-Funded Warrants. The Company determined that the Pre-Funded Warrants are indexed to the Company’s own stock and meet the requirements for equity classification. Proceeds allocated to such warrants totaled $ 0.8 million. During the first quarter of 2023, 1,740,740 Pre-Funded Warrants were exercised for an equivalent number of shares of common stock and 351,852 Pre-Funded Warrants remain outstanding at March 31, 2023 . The Common Stock Warrants have (i) an exercise price per share of common stock equal to $ 1.08 per share, (ii) a cashless exercise option if, at the time of exercise, there is no effective registration statement registering or the prospectus is not available for the issuance of the warrant shares to the holder, with the number of shares received determined according to the formula set forth in the Common Stock Warrant or (iii) an alternate cashless exercise option, which became exercisable on March 15, 2023 , equal to the product of (x) the aggregate number of shares of common stock that would be issuable upon a cash exercise and (y) 0.5. The Common Stock Warrants are exercisable upon issuance and expire on February 17, 2028 . The exercise price and the number of shares of common stock issuable upon exercise of the Common Stock Warrants is subject to adjustment in the event of certain stock dividends and distributions, splits, combinations, reclassifications or similar events affecting the common stock. Holders of the Common Stock Warrants will participate in any distributions to common stockholders as if the holders had exercised the Common Stock Warrants. The Common Stock Warrants are redeemable upon the occurrence of a Fundamental Transaction (as defined in the Common Stock Purchase Warrant Agreement). The Company determined that the Common Stock Warrants are not indexed to the Company’s own stock and therefore are precluded from equity classification. In addition, the Common Stock Warrant liability meets the definition of a derivative instrument. The Common Stock Warrants will be measured at fair value at inception and in subsequent reporting periods with changes in fair value recognized in income as change in fair value of warrant liabilities in the period of change in the condensed consolidated statements of operations and comprehensive loss. The fair value of the Common Stock Warrant liability a t inception was $ 7.6 million. During the first quarter of 2023, 2,344,074 Common Stock Warrants were exercised pursuant to the cashless exercise option resulting in the issuance of 1,172,037 shares of Common Stock. At March 31, 2023, 19,878,148 Common Stock Warrants remain outstanding. The change in fair value after issuance during the three-month period ended March 31, 2023 was a loss of $ 1.3 million . The Company has also issued certain warrants in conjunction with its Term Loan Agreement. (see Note 6).

Stockholders' Deficit

Stockholders' Deficit	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Stockholders' Deficit	8. Stockholders’ Deficit Preferred Stock We have authorized the issuance of up to 10,000,000 shares of $ 0.001 par value preferred stock. The Board of Directors will determine the preferred stock’s rights, preferences, privileges, restrictions, voting rights, dividend rights, conversion rights, redemption privileges, and liquidation preferences. Common Stock We have authorized the issuance of 400,000,000 shares of $ 0.001 par value common stock. Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to the prior rights of holders of all classes of stock outstanding. Equity Distribution Agreement The Company entered into a Sales Agreement with Canaccord Genuity (the “Sales Agreement”), through which the Company may sell up to $ 75.0 million of gross proceeds of common stock. Canaccord, as agent, sells shares at the Company’s request through “at the market” offerings, subject to shelf limitations, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions. Canaccord receives a fee of 3 % of gross proceeds of common stock sold under the Sales Agreement for its services. Legal and accounting fees from sales under the Sales Agreement are charged to share capital. Under the Sales Agreement, the Company sold 653,122 shares of common stock during the three months ended March 31, 2023 for net proceeds of $ 0.9 million, and 70,987 shares of common stock during the three months ended March 31, 2022 for net proceeds of $ 1.4 million.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2023
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	9. Stock-Based Compensation Stock Incentive Plans 2006 Stock Incentive Plan The Company’s 2006 Stock Option Plan (“2006 Plan”) was established for granting stock incentive awards to directors, officers, employees and consultants of the Company. Upon closing of the Company’s IPO in August 2014, the Company ceased granting stock incentive awards under the 2006 Plan. The 2006 Plan provided for the grant of incentive and non-qualified stock options and restricted stock grants as determined by the Company’s board of directors. Under the 2006 Plan, stock options were generally granted with exercise prices equal to or greater than the fair value of the common stock as determined by the board of directors, expired no later than 10 years from the date of grant, and vested over various periods not exceeding 4 years. 2014 Stock Incentive Plan The Company’s 2014 Incentive Award Plan (“2014 Plan”, and together with the 2006 Plan, the “Stock Incentive Plans”) provides for the issuance of shares of common stock in the form of stock options, awards of restricted stock, awards of restricted stock units, performance awards, dividend equivalent awards, stock payment awards and stock appreciation rights to directors, officers, employees and consultants of the Company. Since the establishment of the 2014 Plan, the Company has primarily granted stock options and restricted stock units. Generally, stock options are granted with exercise prices equal to or greater than the fair value of the common stock on the date of grant, expire no later than 10 years from the date of grant, and vest over various periods not exceeding 4 years. The number of shares reserved for future issuance under the 2014 Plan is the sum of (1) 16,470 shares, (2) any shares that were granted under the 2006 Plan which are forfeited, lapse unexercised or are settled in cash subsequent to the effective date of the 2014 Plan and (3) an annual increase on the first day of each calendar year beginning January 1, 2015 and ending on January 1, 2026, equal to the lesser of (A) 4 % of the shares outstanding (on an as-converted basis) on the final day of the immediately preceding calendar year and (B) such smaller number of shares determined by the Company’s board of directors; provided, however, no more than 700,000 shares may be issued upon the exercise of incentive stock options. As of March 31, 2023 , there were 93,387 shares available for future grant under the 2014 Plan. Inducement Award Plan The Company’s Amended and Restated Inducement Award Plan (“Inducement Plan”), which was adopted in March 2018 without stockholder approval pursuant to Rule 5635(c)(4) of The Nasdaq Stock Market LLC listing rules (“Rule 5635(c)(4)”) and most recently amended and restated in December 2021, provides for the grant of equity awards to new employees, including options, restricted stock awards, restricted stock units, performance awards, dividend equivalent awards, stock payment awards and stock appreciation rights. In accordance with Rule 5635(c)(4), awards under the Inducement Plan may only be made to a newly hired employee who has not previously been a member of the Company's Board of Directors, or an employee who is being rehired following a bona fide period of non-employment by us as a material inducement to the employee’s entering into employment with us. The aggregate number of shares of common stock which may be issued or transferred pursuant to awards under the Inducement Plan is 192,500 shares. Any awards that forfeit, expire, lapse, or are settled for cash without the delivery of shares to the holder are available for the grant of an award under the Inducement Plan. Any shares repurchased by or surrendered to the Company that are returned shall be available for the grant of an award under the Inducement Plan. The payment of dividend equivalents in cash in conjunction with any outstanding award shall not be counted against the shares available for issuance under the Inducement Plan. As of March 31, 2023 , there were 52,689 shares available for future grant under the Inducement Plan. Stock Options The aggregate fair value of stock options granted during the three months ended March 31, 2023 was immaterial. During the three months ended March 31, 2022, the Company granted stock options with an aggregate fair value of $ 0.2 mil lion, respectively, which are being amortized into compensation expense over the vesting period of the options as the services are being provided. The following is a summary of option activity under the Stock Incentive Plans and Inducement Plan (in thousands, except share and per share amounts): Number of Weighted-Average Weighted-Average Aggregate Intrinsic Outstanding at December 31, 2022 179,641 $ 145.09 5.93 $ — Granted 6,220 1.59 Exercised — — — — Forfeited ( 3,981 ) 21.95 Cancelled ( 14,434 ) 149.80 Outstanding at March 31, 2023 167,446 $ 142.28 6.19 $ — Exercisable at March 31, 2023 126,982 $ 175.16 5.56 $ — Vested or expected to vest at March 31, 2023 161,179 $ 146.59 6.09 $ — There were no options exercised in the three months ended March 31, 2023 and March 31, 2022. The weighted-average grant date fair values of stock options granted in the three month periods ended March 31, 2023 and 2022 wer e $ 1.34 per share and $ 16.57 per share, respectively, and were calculated using the following estimated assumptions: Three Months Ended March 31, 2023 2022 Weighted-average risk-free interest rate 3.65 % 1.67 % Expected dividend yield — % — % Expected volatility 111 % 105 % Expected terms 6.0 years 6.0 years The total fair values of options that vested during the three months ended March 31, 2023 and 2022 were $ 0.3 million and $ 0.6 million, respectively. As of March 31, 2023, there was $ 1.2 million of total unrecognized compensation cost related to non-vested stock options granted under the Stock Incentive Plans and Inducement Plan. Total unrecognized compensation cost will be adjusted for future changes in the estimated forfeiture rate. The Company expects to recognize that cost over a remaining weighted-average period of 1.6 years as of March 31, 2023. Restricted Stock Units During the three months ended March 31, 2023, the Company awarded restricted stock units to certain employees and directors at no cost to them. The restricted stock units, excluding any restricted stock units with market conditions, vest through the passage of time, assuming continued service. Restricted stock units are not included in issued and outstanding common stock until the underlying shares are vested and released. The fair value of the restricted stock units, at the time of the grant, is expensed on a straight line basis. The granted restricted stock units had an aggregate fair value of $ 0.2 m illion, which are being amortized into compensation expense over the vesting period of the restricted stock units as the services are being provided. The following is a summary of restricted stock unit activity under the 2014 Plan and Inducement Plan: Number of Weighted-Average Nonvested at December 31, 2022 201,998 $ 44.47 Granted 339,950 0.67 Vested ( 67,526 ) 55.27 Forfeited ( 4,470 ) 38.99 Nonvested at March 31, 2023 469,952 $ 11.28 As of March 31, 2023 , there was $ 4.9 million of total unrecognized compensation cost related to nonvested restricted stock units granted. Total unrecognized compensation cost will be adjusted for future changes in the estimated forfeiture rate. The Company expects to recognize that cost over a remaining weighted-average period of 1.3 years, as of March 31, 2023. Employee Stock Purchase Plan Under the 2014 Employee Stock Purchase Plan (the “2014 ESPP”) participants may purchase the Company’s common stock during semi-annual offering periods at 85 % of the lower of (i) the market value per share of common stock on the first day of the offering period or (ii) the market value per share of the common stock on the purchase date. Each participant can purchase up to a maximum of $ 25,000 per calendar year in fair market value as calculated in accordance with applicable tax rules. The first offering period began on August 7, 2014. Stock-based compensation expense from the 2014 ESPP was immaterial for the three months ended March 31, 2023 and was $ 0.1 million for the three months ended March 31, 2022. The 2014 ESPP, which was amended and restated effective August 6, 2020, provides for the issuance of up to 90,478 shares of the Company’s common stock to eligible employees. At March 31, 2023, there were 22,849 shares available for issuance under the 2014 ESPP. Stock-Based Compensation Expense The following table summarizes the stock-based compensation expense resulting from awards granted under Stock Incentive Plans, the Inducement Plan and the 2014 ESPP, that was recorded in the Company’s results of operations for the periods presented (in thousands): Three Months Ended 2023 2022 Cost of product revenue $ 54 $ 129 Research and development 280 422 Selling, general and administrative 1,462 1,994 Total stock-based compensation expense $ 1,796 $ 2,545 For the three months ended March 31, 2023 and 2022, stock-based compensation expenses capitalized as part of inventory or T2Dx instruments and components were immaterial.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Net Loss Per Share	10. Net Loss Per Share The Company applies the two-class method for computing earnings per share because its Series A Warrants, Pre-Funded Warrants and Common Stock Warrants are participating securities. Under the two-class method, net income for the period is allocated between common stockholders and holders of the participating securities according to dividends declared, if any, and participation rights in undistributed earnings. Because the Company incurred a net loss for the three months ended March 31, 2023, and the holders of the participating securities do not have the contractual obligation to share in the losses of the Company, none of the net loss attributable to common stockholders was allocated to the participating securities when computing earnings per share. The Company did not have any participating securities outstanding for the three-month period ended March 31, 2022. The Pre-Funded Warrants allow the holders to acquire a specified number of common shares at a nominal exercise price of $ 0.001 per share and are classified as equity. Since the shares underlying the Pre-Funded Warrants are exercisable for little or no consideration, the underlying shares are considered outstanding at the issuance of the Pre-Funded Warrants for purposes of calculating the weighted-average number of shares of common stock outstanding in basic and diluted earnings per share. The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock or if-converted methods, because their effect would have been anti-dilutive for the periods presented: Three Months Ended 2023 2022 Options to purchase common shares 167,446 198,393 Restricted stock units 469,952 257,867 Term Loan Warrants 21,944 21,944 Series A Warrant 42,857 — Common Stock warrants 19,878,148 — Total 20,580,347 478,204

US Government Contract

US Government Contract	3 Months Ended
	Mar. 31, 2023
Organization Consolidation And Presentation Of Financial Statements [Abstract]
US Government Contract	11. U.S. Government Contract In September 2019, BARDA awarded the Company a milestone-based contract, with an initial value of $ 6.0 million, and a potential value of up to $ 62.0 million, if BARDA awards all contract options (the “U.S. Government Contract”). BARDA operates within the Office of the Assistant Secretary for Preparedness and Response (“ASPR”) at the U.S. Department of Health and Human Services (“HHS”). If BARDA awards and the Company completes all options, the Company’s management believes it will enable a significant expansion of the Company’s current portfolio of diagnostics for sepsis-causing pathogen and antibiotic resistance genes. In September 2020, BARDA exercised the first contract option valued at $ 10.5 million. In September 2021, BARDA exercised an option valued at approximately $ 6.4 million. In April 2021, BARDA agreed to accelerate product development by modifying the contract to advance future deliverables into the currently funded Option 1 of the BARDA contract for T2NxT, T2Biothreat, T2Resistance and T2AMR. The modification does not change the overall total potential value of the BARDA contract. On March 31, 2022, the Company announced that BARDA had exercised Option 2B under the existing multiple-year cost-share contract between BARDA and the Company and is providing an additional $ 4.4 million in funding to the Company. The option exercise occurred simultaneously on March 31, 2022 with a modification to the BARDA contract to make immaterial changes to, among other things, the statement of work. In September 2022, BARDA exercised Option 3 and agreed to provide an additional $ 3.7 million in funding for the multiple-year cost-share contract. The additional funding under Option 3 will be used to advance the U.S. clinical trials for the T2Biothreat ® Panel and T2Resistance ® Panel, and to file submissions to the FDA for U.S. regulatory clearance. The Company recorded contribution revenue of $ 0.4 million and $ 3.4 million for the three months ended March 31, 2023 and 2022, respectively, under the BARDA contract. The Company had no outstanding accounts receivable at March 31, 2023 and unbilled accounts receivable of $ 0.7 million at December 31, 2022, respectively, under the BARDA contract.

Leases

Leases	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Leases	12. Leases Operating Leases The Company leases certain office space, laboratory space and manufacturing space. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. The Company does no t recognize right-of-use assets or lease liabilities for leases determined to have a term of twelve months or less. The Company has elected to account for the lease and associated non-lease components as a combined lease component. In August 2010, the Company entered into an operating lease for office and laboratory space at its headquarters in Lexington, Massachusetts. The lease commenced in January 2011, with the Company providing a security deposit of $ 400,000 . In accordance with the operating lease agreement, the Company reduced its security deposit to $ 160,000 in January 2018, which is recorded as restricted cash in the condensed consolidated balance sheets. In March 2017, the Company entered into an amendment to extend the term to December 2021 . In October 2020, the Company entered into an amendment to extend the term to December 31, 2028 . In accordance with the October 2020 amendment, the Company increased its security deposit to $ 420,438 , which is classified as restricted cash at March 31, 2023 and December 31, 2022. In May 2013, the Company entered into an operating lease for additional office, laboratory and manufacturing space in Wilmington, Massachusetts. In August 2018, the Company entered into an amendment to extend the term to December 2020 . In October 2020, the Company entered into an amendment to extend the term to December 31, 2022 . In September 2022, the Company entered into an amendment to extend the term to December 31, 2024 . In November 2014, the Company entered into a lease for additional laboratory space in Lexington, Massachusetts. The lease term commenced in April 2015 and extended for six years . The rent expense, inclusive of the escalating rent payments, is recognized on a straight-line basis over the lease term. As an incentive to enter into the lease, the landlord paid approximately $ 1.4 million of the $ 2.2 million space build-out costs. The unamortized balance of the lease incentive as of January 1, 2019 was reclassified as a reduction to the initial recognition of the right-of-use asset related to this lease. In connection with this lease agreement, the Company paid a security deposit of $ 281,000 , which was recorded as a component of both prepaid expenses and other current assets and other assets in the condensed consolidated balance sheets at December 31, 2019. In October 2020, the Company entered into an amendment to extend the term of the lease to October 31, 2025 . In accordance with this amendment, the Company paid a replacement security deposit of $ 130,977 , which is classified as restricted cash at March 31, 2023 and December 31, 2022 and received the initial $ 281,000 security deposit in return. In September 2021, the Company entered into a lease for office, research, laboratory and manufacturing space in Billerica, Massachusetts. The lease has a term of 126 months from the commencement date. The Company opened a money market account for $ 1.0 million, which represents collateral as a security deposit for this lease and is classified as restricted cash at December 31, 2022 and 2021. Occupancy of the building had been delayed due to disagreement between the Company and the landlord as to the parties’ obligations under the lease agreement. Included within accrued expenses and other current liabilities on the balance sheet at December 31, 2022 is a $ 1.0 million estimated liability pertaining to this lease. Subsequent to December 31, 2022, the Company was notified that the landlord terminated the lease because of the Company’s alleged failure to perform its obligations under the Lease in a timely manner and the Company’s alleged breach of the covenant of good faith and fair dealing and exercised its right to draw upon the $ 1.0 million se curity deposit. In addition, the landlord is seeking damages for unpaid rent, brokerage fees, transaction costs, attorney’s fees and court costs. The Company filed a response to the landlord’s complaint and a counterclaim alleging that the landlord breached its obligations under the contract and unlawfully drew on the security deposit, in addition to breaching its covenants of good faith and fair dealing, making fraudulent misrepresentations, and engaging in deceptive and unfair trade practices. The matter is in dispute (Note 13). Operating leases are amortized over the lease term and included in costs and expenses in the condensed consolidated statement of operations and comprehensive loss. Variable lease costs are recognized in costs and expenses in the condensed consolidated statement of operations and comprehensive loss as incurred. Variable lease costs may include costs such as common area maintenance, utilities, real estate taxes or other costs. Expenses related to short-term leases were not material for periods presented.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	13. Commitments and Contingencies Contingencies In September 2021, the Company entered into a lease for office, research, laboratory and manufacturing space in Billerica, Massachusetts. The lease has a term of 126 months from the commencement date. The Company opened a money market account for $ 1.0 million, which represents collateral as a security deposit for this lease and is classified as restricted cash at December 31, 2022 and 2021. Occupancy of the building had been delayed due to disagreement between the Company and the landlord as to the parties’ obligations under the lease agreement. Included within accrued expenses and other current liabilities on the balance sheet at December 31, 2022 is a $ 1.0 million estimated liability pertaining to this lease. Subsequent to December 31, 2022, the Company was notified that the landlord terminated the lease because of the Company’s alleged failure to perform its obligations under the Lease in a timely manner and the Company’s alleged breach of the covenant of good faith and fair dealing and exercised its right to draw upon the $ 1.0 million se curity deposit. In addition, the landlord is seeking damages for unpaid rent, brokerage fees, transaction costs, attorney’s fees and court costs. The Company filed a response to the landlord’s complaint and a counterclaim alleging that the landlord breached its obligations under the contract and unlawfully drew on the security deposit, in addition to breaching its covenants of good faith and fair dealing, making fraudulent misrepresentations, and engaging in deceptive and unfair trade practices. The Company intends to vigorously defend itself and pursue all legal remedies available under applicable laws. The Company believes it will continue to meet its current manufacturing needs with its operations at its Lexington and Wilmington, Massachusetts facilities. License Agreement In 2006, the Company entered into a license agreement with a third party, pursuant to which the third party granted the Company an exclusive, worldwide, sublicensable license under certain patent rights to make, use, import and commercialize products and processes for diagnostic, industrial and research and development purposes. The Company agreed to pay an annual license fee ranging from $ 5,000 to $ 25,000 for the royalty‑bearing license to certain patents. The Company also issued a total of 1,693 shares of common stock pursuant to the agreement in 2006 and 2007, which were recorded at fair value at the date of issuance. The Company is required to pay royalties on net sales of products and processes that are covered by patent rights licensed under the agreement at a percentage ranging between 0.5 % - 3.5 %, subject to reductions and offsets in certain circumstances, as well as a royalty on net sales of products that the Company sublicenses at 10 % of specified gross revenue. Royalties that became due under this agreement for the three months ended March 31, 2023 and 2022 were immaterial. Letter Agreements On March 30, 2023, the Company entered into letter agreements with Mr. Sprague, Mr. Giffin, and Mr. Gibbs that provide for the payment of a retention bonus in the total aggregate amount of $ 80,000 , to be paid in two installments of $40,000. The first installment, in the amount of $ 40,000 , shall be paid within five business days following June 30, 2023, and the second installment, in the amount of $ 40,000 , shall be paid within five business days following November 15, 2023. Each such installment payment is subject to the respective executive's continued employment through such payment date.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events Waiver and Consent to Term Loan Agreement with CRG On May 19, 2023, the Term Loan Agreement with CRG was amended to reduce the minimum cash covenant to $ 500,000 .

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company’s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). The Company’s condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, T2 Biosystems Securities Corporation. All intercompany balances and transactions have been eliminated. On October 12, 2022, we effected a 50 for 1 reverse stock split. One share of common stock was issued for every 50 shares of issued and outstanding , fractional shares were settled in cash and adjustment made for 50 shares of rounding. A ll references to share and per share amounts (excluding authorized shares) in the condensed consolidated financial statements and accompanying notes have been retroactively restated to for the reverse split.
Unaudited Interim Financial Information	Unaudited Interim Financial Information Certain information and footnote disclosures normally included in the Company’s annual financial statements have been condensed or omitted. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The accompanying interim condensed consolidated balance sheet as of March 31, 2023, the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2023 and 2022, the condensed consolidated statements of stockholders’ deficit for the three months ended March 31, 2023 and 2022, the condensed consolidated statements of cash flows for the three months ended March 31, 2023 and 2022 and the related financial data and other information disclosed in these notes are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual financial statements, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of March 31, 2023, and the results of its operations for the three months ended March 31, 2023 and 2022 and its cash flows for the three months ended March 31, 2023 and 2022. The results for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 , any other interim periods, or any future year or period.
Reclassification	Reclassification Certain prior year amounts have been reclassified to conform to the current year presentation. Such reclassifications had no impact on the Company's reported total revenues, expenses, net loss, current assets, total assets, current liabilities, total liabilities, stockholders' equity (deficit) or cash flows. No reclassifications of prior period balances were material to the consolidated financial statements.
Segment Information	Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision‑making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is the Chief Executive Officer. The Company views its operations and manages its business in one operating segment, which is the business of developing and, upon regulatory clearance, launching commercially its diagnostic products aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier.
Going Concern	Going Concern Pursuant to the requirements of Accounting Standards Codification 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern ("ASC 205-40"), management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued.
Geographic Information	Geographic Information The Company sells its products domestically and internationally. Total international sales were approximately $ 0.8 million or 36 % of total revenue and $ 1.0 million or 13 % of total revenue for the three months ended March 31, 2023 and 2022, respectively. International sales to Italy was $ 0.4 million or 19 % of total revenue for the three months ended March 31, 2023. International sales to any customer in a single country did not exceed 10 % of total revenue for the three months ended March 31, 2022. The following table shows customers that represent greater than 10% of total revenue for the period presented: Three Months Ended 2023 2022 Customer A 20 % 47 % Customer B 19 % 5 % Customer A is a U.S. government customer (BARDA). Customer B is an international distributor. The following table shows customers that represent greater than 10% of the accounts receivable balance for the period presented: March 31, December 31, Customer A — % 32 % Customer B 28 % — % Customer A is a U.S. government customer (BARDA). Customer B is an international distributor. As of March 31, 2023 and December 31, 2022, the Company had outstanding receivables of $ 1.4 million and $ 0.4 million, respectively, from customers located outside of the U.S.
Net Loss Per Share	Net Loss Per Share The Company has issued certain securities that are participating securities; therefore, the Company must apply the two-class method to determine basic and diluted earnings per share. To the extent that a dividend or distribution is declared or paid during the period, the Company applies the two-class method to determine the allocation of the dividends or distributions between the common shareholders and the holders of the participating securities. The Company’s participating securities do not have an obligation to share in the losses of the Company. To the extent that the Company remains in a net loss position, the two-class method will not apply since the entire net loss would be allocated to the common shareholders. Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period and potential common shares exercisable for little to no consideration, without consideration for other common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding and potential common shares exercisable for little to no consideration used to compute basic earnings per share for the dilutive effect of other common stock equivalents that were outstanding during the period, determined using either the if-converted method or the treasury-stock method.
Derivative Instruments	Derivative Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives requiring bifurcation in accordance with ASC Topic 815, Derivatives and Hedging . Derivative instruments are measured at fair value at issuance and at each reporting date in accordance with ASC 820 with changes in fair value recognized in the period of change in the condensed consolidated statements of operations and comprehensive loss. The Company determined that both the warrant issued in conjunction with the Series A redeemable convertible preferred stock in August of 2022 and the Common Stock Warrants issued in February 2023 are derivative instruments. The warrant liabilities are classified on the condensed consolidated balance sheets as current because settlement of the warrant liability could be required by the holder within 12 months of the balance sheet date. Changes in fair value are recognized in change in fair value of warrant liabilities in the period of change in the condensed consolidated statements of operations and comprehensive loss. See Notes 3 and 7. The Company has identified a single compound derivative liability related to its Term Loan Agreement with CRG, that is classified as non-current on the condensed consolidated balance sheets to match the classification of the related Term Loan Agreement. Changes in fair value are recognized in change in fair value of derivative related to Term Loan in the period of change in the condensed consolidated statements of operations and comprehensive loss. See Note 6. The Company does not designate its derivative instruments as hedging instruments.
Guarantees	Guarantees As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while each such officer or director is, or was, serving at the Company’s request in such capacity. The term of the indemnification is the officer’s or director’s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors’ and officers’ liability insurance coverage that limits its exposure and enables the Company to recover a portion of any future amounts paid. The Company leases office, laboratory and manufacturing space under noncancelable operating leases. The Company has standard indemnification arrangements under the leases that require it to indemnify the landlords against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation or nonperformance of any covenant or condition of the Company’s leases. See Note 13 for a discussion about the Billerica, Massachusetts lease. In the ordinary course of business, the Company enters into indemnification agreements with certain suppliers and business partners where the Company has certain indemnification obligations limited to the costs, expenses, fines, suits, claims, demands, liabilities and actions directly resulting from the Company’s gross negligence or willful misconduct, and in certain instances, breaches, violations or nonperformance of covenants or conditions under the agreements. As of March 31, 2023 and December 31, 2022 , the Company had not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.
Leases	Leases Lessee Pursuant to ASC Topic 842, Leases (“ASC 842”), at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less. The exercise of lease renewal options is at the Company's discretion and the periods subject to renewal option are not included in the measurement of the Company’s right-of-use assets and lease liabilities as the renewal options are not reasonably certain of exercise. The Company will continue to evaluate the renewal options and when they are reasonably certain of exercise, the Company will include the renewal period in its lease term. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. However, certain adjustments to the right-of-use asset may be required for items such as prepaid or accrued lease payments. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. In accordance with the guidance in ASC 842, components of a lease should be split into three categories: lease components (e.g. land, building, etc.), non-lease components (e.g. common area maintenance, consumables, etc.), and non-components (e.g. property taxes, insurance, etc.). Then the fixed and in-substance fixed contract consideration (including any related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. The Company made the policy election to not separate lease and associated non-lease components. Each lease component and the related non-lease components are accounted for together as a single component. Lessor The Company derives revenue from leasing its T2-owned instruments through reagent rental agreements (see the Revenue Recognition section below). Customers typically have the right to cancel every twelve months but subject to penalty. As a result of the penalty, the customers are deemed reasonably certain of not exercising their termination rights resulting in a lease term of generally three years. These lease agreements impose no requirement on the customer to purchase the instrument, and the instrument is not transferred to the customer at the end of the lease term. The short-term nature of the lease agreements does not result in lease payments accumulating to an amount that exceeds substantially all of the fair value of the instrument nor is the lease term for the majority of the remaining economic life of the instrument. Instrument leases are generally classified as operating leases as they do not meet any of the sales-type lease or direct financing lease criteria per ASC 842 and are recognized ratably over the duration of the lease. In accordance with these contracts, customers only make payments when consumables are ordered and delivered thus making these payments variable by nature. The Company estimates the expected volume of consumables to be purchased by each customer over the lease term to measure and recognize rental and consumables revenue. Generally, lease arrangements include both lease and non-lease components. The lease component relates to the customer’s right-to-use the T2-owned instrument over the lease term. The non-lease components relate to (1) consumables and (2) maintenance services. Because the timing and pattern of transfer for the operating lease component, the T2-owned instrument, and maintenance components of a reagent rental agreement are recognized over the same time period and in the same pattern, the Company elected the practical expedient to aggregate non-lease components with the associated lease component and account for the combined component as an operating lease for all instrument leases. In the evaluation of whether the lease component (T2-owned instrument) or the non-lease component associated with the lease component (maintenance) is the predominant component, the Company determined that the lease component is predominant as we believe the customer would ascribe more value to the use of the T2-owned instrument than that of the maintenance services. The T2-owned instrument lease and maintenance service performance obligations are classified as a single category of instrument rental revenue within product revenue in the condensed consolidated statements of operations and comprehensive loss (see disaggregated revenue table below in Revenue Recognition section). The consumables non-lease component does not meet the requirements to elect the practical expedient and thus must apply ASC Topic 606, Revenue from Contracts with Customers , as described below in the Revenue Recognition section. The Company considers the economic life of its T2-owned instruments to be five years. The Company believes five years is representative of the period during which the instrument is expected to be economically usable by one or more users, with normal service, for the purpose for which it is intended. The residual value is estimated to be the value at the end of the lease term based on the anticipated fair market value of the units. The Company mitigates residual value risk of its leased instrument by performing regular management and maintenance, as necessary.
Revenue Recognition	Revenue Recognition The Company generates revenue from the sale of instruments, consumable diagnostic tests, related services, reagent rental agreements and government contributions. For arrangements in the scope of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”), the Company determines revenue recognition through the following steps: • Identification of a contract with a customer • Identification of the performance obligations in the contract • Determination of the transaction price • Allocation of the transaction price to the performance obligations • Recognition of revenue as a performance obligation is satisfied The amount of revenue recognized reflects the consideration the Company expects to be entitled to receive in exchange for these goods and services. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. Generally, the Company's performance obligations are transferred to customers either at a point in time, typically upon shipment, or over time, as services are performed. Most of the Company’s contracts with distributors in geographic regions outside the United States contain only a single performance obligation, whereas most of the Company’s contracts with direct sales customers in the United States contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately if they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. Excluded from the transaction price are sales tax and other similar taxes which are presented on a net basis. Product revenue is generated by the sale of instruments and consumable diagnostic tests predominantly through the Company’s direct sales force in the United States and distributors in geographic regions outside the United States. The Company generally does not offer product returns or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including its distributors. Payment terms granted to distributors are the same as those granted to end-user customers and payments are not dependent upon the distributors’ receipt of payment from their end-user customers. The Company either sells instruments to customers and international distributors, or retains title and places the instrument at the customer site pursuant to a reagent rental agreement. When an instrument is purchased by a customer or international distributor, the Company recognizes revenue when the related performance obligation is satisfied (i.e. when the control of an instrument has passed to the customer; typically, at shipping point). When the instrument is placed under a reagent rental agreement, the Company’s customers generally agree to fixed term agreements, which can be extended, and incremental charges on each consumable diagnostic test purchased. Revenue from the sale of consumable diagnostic tests (under a reagent rental agreement) is generally recognized upon shipment. The transaction price from consumables purchases is allocated between the lease and nonlease components when related performance obligations are satisfied, as a component of lease and product revenue, and is included as Instrument Rentals in the below table. Revenue associated with reagent rental consumables purchases is currently classified as variable consideration and constrained until a purchase order is received and related performance obligations have been satisfied. Revenue from the sale of consumable diagnostic tests (under instrument purchase agreements) is recognized when control has passed to the customer, typically at shipping point. Shipping and handling costs billed to customers in connection with a product sale are recorded as a component of the transaction price and allocated to product revenue in the condensed consolidated statements of operations and comprehensive loss as they are incurred by the Company in fulfilling its performance obligations. Direct sales of instruments include warranty, maintenance and technical support services typically for one year following the installation of the purchased instrument (“Maintenance Services”). Maintenance Services are separate performance obligations as they are service based warranties and are recognized on a straight-line basis over the service delivery period. After the completion of the initial Maintenance Services period, customers have the option to renew or extend the Maintenance Services typically for additional one year periods in exchange for additional consideration. The extended Maintenance Services are also service based warranties that represent separate purchasing decisions. The Company recognizes revenue allocated to the extended Maintenance Services performance obligation on a straight-line basis over the service delivery period. Fees paid to member-owned group purchasing organizations (“GPOs”) are deducted from related product revenues. The Company warrants that consumable diagnostic tests will be free from defects, when handled according to product specifications, for the stated life of the product. To fulfill valid warranty claims, the Company provides replacement product free of charge. Warranty expense is recognized based on the estimated defect rates of the consumable diagnostic tests. Contribution Revenue The government contract with BARDA is considered a government grant and not considered a contract with a customer and thus not subject to ASC 606. Revenue under the government BARDA contract is earned under a cost-sharing arrangement in which the Company is reimbursed for direct costs incurred plus allowable indirect costs. The government contract revenue is recognized as the related reimbursable expenses are incurred. The cost reimbursement that is reported as revenue is presented gross of the related reimbursable expenses in the Company’s condensed consolidated statements of operations and comprehensive loss; the related reimbursable expenses are expensed as incurred as research and development expense. The Company accounts for these contracts as a government grant by analogy to International Accounting Standards 20 (“IAS 20”), Accounting for Government Grants and Disclosure of Government Assistance. The Company has a significant development contract with BARDA and should BARDA reduce, cancel or not grant additional milestone projects, the Company’s ability to continue future product development may be adversely impacted. Refer to Note 11 for further details regarding the development contract with BARDA. Disaggregation of Revenue The Company disaggregates revenue from contracts with customers by type of products and services, as it best depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. The following table disaggregates our revenue by major source (in thousands): Three Months Ended, 2023 2022 Product revenue Instruments $ 322 $ 646 Consumables 1,177 2,950 Instrument rentals 55 18 Service 101 230 Total product revenue 1,655 3,844 Contribution revenue 423 3,390 Total revenue $ 2,078 $ 7,234 Remaining Performance Obligations Under ASC 606, the Company is required to disclose the aggregate amount of the transaction price that is allocated to unsatisfied or partially satisfied performance obligations as of March 31, 2023. However, the guidance provides certain practical expedients that limit this requirement, and therefore, the Company has elected to not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. The nature of the excluded unsatisfied performance obligations pursuant to the practical expedient include consumable shipments, service contracts, warranties and installation services that will be performed within one year . The amount of the transaction price that is allocated to unsatisfied or partially satisfied performance obligations, that has not yet been recognized as revenue and that does not meet the elected practical expedient is $ 0.2 million as of March 31, 2023. The Company expects to recognize 53 % of this amount as revenue within one year and the remainder within three years . Judgments Certain contracts with customers include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment. Once the performance obligations are determined, the Company determines the transaction price, which includes estimating the amount of variable consideration, based on the most likely amount, to be included in the transaction price, if any. The Company then allocates the transaction price to each performance obligation in the contract based on a relative standalone selling price method. The corresponding revenue is recognized as the related performance obligations are satisfied as discussed in the revenue categories above. Judgment is required to determine the standalone selling price for each distinct performance obligation. The Company determines standalone selling price based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as a range of selling prices, market conditions and the expected costs and margin related to the performance obligations. Contract Assets and Liabilities At March 31, 2023 and December 31, 2022, the Company recorded $ 0.2 million and $ 0.1 million, respectively, of contract assets within other assets on the balance sheet. The contract assets represent revenue recognized for performance obligations in advance of invoicing at the contract level based on the transaction price allocated to the respective performance obligations. The Company’s contract liabilities consist of upfront payments for research and development contracts and maintenance services on instrument sales. Contract liabilities are classified in deferred revenue as current or non-current based on the timing of when revenue is expected to be recognized. At March 31, 2023 and December 31, 2022, the Company had contract liabilities of $ 0.2 million and $ 0.2 million, respectively. Revenue recognized during the three months ended March 31, 2023 relating to contract liabilities at December 31, 2022 was $ 0.1 million and related to straight-line revenue recognition associated with maintenance agreements.
Cost of Product Revenue	Cost of Product Revenue Cost of product revenue includes the cost of materials, direct labor and manufacturing overhead costs used in the manufacture of consumable diagnostic tests sold to customers, related warranty and license and royalty fees. Cost of product revenue also includes depreciation on T2-owned revenue generating T2Dx instruments that have been placed with customers under reagent rental agreements; costs of materials, direct labor and manufacturing overhead costs on the T2Dx instruments sold to customers; and other costs such as customer support costs, royalties and license fees, warranty and repair and maintenance expense on the T2Dx instruments that have been placed with customers under reagent rental agreements.
Research and Development Costs	Research and Development Costs Costs incurred in the research and development of the Company’s product candidates are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including activities associated with delivering products or services associated with contribution revenue, clinical trials to evaluate the clinical utility of product candidates, and costs associated with the enhancements of developed products. These costs include salaries and benefits, stock compensation, research related facility and overhead costs, laboratory supplies, equipment, depreciation on T2Dx instruments used for research and development activities and contract services.
Selling, General and Administrative Expenses	Selling, General and Administrative Expenses Selling, general and administrative expenses consist primarily of costs for our sales and marketing, finance, legal, human resources, business development and general management functions, as well as professional services, such as legal, consulting and accounting services. Other selling, general and administrative expenses include commercial support activity, facility-related costs, fees and expenses associated with obtaining and maintaining patents, clinical and economic studies and publications, marketing expenses, and travel expenses. We expense the majority of selling, general and administrative expenses as incurred.
Recent Accounting Standards	Recent Accounting Standards From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. Accounting Standards Adopted On September 29, 2022, the FASB issued ASU 2022-04, Liabilities-Supplier Finance Programs (Subtopic 405-50) Disclosure of Supplier Finance Program Obligations. This ASU requires that a buyer in a supplier finance program disclose additional information about the program to allow financial statement users to better understand the effect of the programs on an entity's working capital, liquidity, and cash flows. This update is effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the amendment on roll forward information, which is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted. The Company adopted ASU 2022-04 on January 1, 2023. The adoption did not have a material impact on the Company's financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Schedule of Customers Represent Greater Than 10% Of Revenue	The following table shows customers that represent greater than 10% of total revenue for the period presented: Three Months Ended 2023 2022 Customer A 20 % 47 % Customer B 19 % 5 % Customer A is a U.S. government customer (BARDA). Customer B is an international distributor.
Schedule of Customers Represent Greater Than 10% Of Accounts Receivable	The following table shows customers that represent greater than 10% of the accounts receivable balance for the period presented: March 31, December 31, Customer A — % 32 % Customer B 28 % — %
Disaggregation of Revenue by Major Source	The following table disaggregates our revenue by major source (in thousands): Three Months Ended, 2023 2022 Product revenue Instruments $ 322 $ 646 Consumables 1,177 2,950 Instrument rentals 55 18 Service 101 230 Total product revenue 1,655 3,844 Contribution revenue 423 3,390 Total revenue $ 2,078 $ 7,234

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities at Fair value on a Recurring Basis	The Company measures the following financial assets at fair value on a recurring basis. There were no transfers between levels of the fair value hierarchy during any of the periods presented. The following tables set forth the Company’s financial assets and liabilities carried at fair value categorized using the lowest level of input applicable to each financial instrument as of March 31, 2023 and December 31, 2022 (in thousands): Balance at Quoted Prices Significant Significant Liabilities: Warrant liabilities $ 7,972 $ — $ 16 $ 7,956 Derivative liability related to Term Loan 1,858 — — 1,858 $ 9,830 $ — $ 16 $ 9,814 Balance at Quoted Prices Significant Significant Liabilities Warrant liabilities $ 39 $ — $ 39 $ — Derivative liability related to Term Loan 1,088 — — 1,088 $ 1,127 $ — $ 39 $ 1,088
Schedule of Estimated Fair Value of the Warrant Liability	The estimated fair value of the Series A Warrant at March 31, 2023 was determined using the following assumptions: Risk-free interest rate 3.61 % Expected dividend yield 0.00 % Expected volatility 120.00 % Expected term 4.88
Schedule of Roll-forward of Fair Value of Common Stock Warrants	The following table provides a roll-forward of the fair value of the Common Stock Warrants (in thousands): Balance at December 31, 2022 $ — Issuance of Common Stock Warrant 7,568 Settlement due to cashless exercise ( 938 ) Change in fair value 1,326 Balance at March 31, 2023 $ 7,956
Summary of Contingent Interest Payments	The estimated fair value of the derivative at March 31, 2023 was determined using a probability-weighted discounted cash flow model that includes contingent interest payments under the following scenarios: Probability 4 % contingent interest beginning in Q3 2023 60 %
Roll-Forward of Fair Value of Derivative Liability related to Term Loan	The following table provides a roll-forward of the fair value of the derivative liability related to the Term Loan (in thousands): Balance at December 31, 2022 $ 1,088 Change in fair value of derivative related to Term Loan 770 Balance at March 31, 2023 $ 1,858

Supplemental Balance Sheet In_2

Supplemental Balance Sheet Information (Tables)	3 Months Ended
	Mar. 31, 2023
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Inventory	Inventories are stated at the lower of cost or net realizable value on a first-in, first-out basis and are comprised of the following (in thousands): March 31, December 31, Raw materials $ 2,571 $ 2,004 Work-in-process 1,674 1,176 Finished goods 691 1,105 Total inventories, net $ 4,936 $ 4,285
Schedule of Property and Equipment	Property and equipment consist of the following (in thousands): March 31, December 31, Office and computer equipment $ 757 $ 757 Software 783 783 Laboratory equipment 5,594 5,570 Furniture 210 197 Manufacturing equipment 1,454 1,454 Manufacturing tooling and molds 494 494 T2-owned instruments and components 4,285 4,052 Leased T2-owned instruments 1,011 1,014 Leasehold improvements 3,785 3,784 Construction in progress 869 685 19,242 18,790 Less accumulated depreciation and amortization ( 14,441 ) ( 14,257 ) Property and equipment, net $ 4,801 $ 4,533
Components of Accrued Expenses	Accrued expenses consist of the following (in thousands): March 31, December 31, Accrued payroll and compensation $ 2,270 $ 2,930 Accrued clinical trial and development expenses 826 1,097 Accrued professional services 604 1,626 Accrued interest 996 1,009 Other accrued expenses 466 607 Total accrued expenses and other current liabilities $ 5,162 $ 7,269 Accrued professional services at December 31, 2022 includes a $ 1.0 million estimated liability related to the Billerica, Massachusetts lease (Note 13).

Notes Payable (Tables)

Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Schedule of Debt	Future principal payments on the notes payable are as follows (in thousands): March 31, December 31, Term Loan Agreement including PIK interest, before unamortized discount and issuance costs $ 53,453 $ 53,453 Less: unaccrued paid-in-kind interest ( 3,211 ) ( 3,647 ) Less: unamortized discount and deferred issuance costs ( 134 ) ( 155 ) Total notes payable $ 50,108 $ 49,651

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2023
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Option Activity	The following is a summary of option activity under the Stock Incentive Plans and Inducement Plan (in thousands, except share and per share amounts): Number of Weighted-Average Weighted-Average Aggregate Intrinsic Outstanding at December 31, 2022 179,641 $ 145.09 5.93 $ — Granted 6,220 1.59 Exercised — — — — Forfeited ( 3,981 ) 21.95 Cancelled ( 14,434 ) 149.80 Outstanding at March 31, 2023 167,446 $ 142.28 6.19 $ — Exercisable at March 31, 2023 126,982 $ 175.16 5.56 $ — Vested or expected to vest at March 31, 2023 161,179 $ 146.59 6.09 $ —
Schedule of Estimated Assumptions Used to Calculate Weighted-Average Grant Date Fair Value of Options Granted	There were no options exercised in the three months ended March 31, 2023 and March 31, 2022. The weighted-average grant date fair values of stock options granted in the three month periods ended March 31, 2023 and 2022 wer e $ 1.34 per share and $ 16.57 per share, respectively, and were calculated using the following estimated assumptions: Three Months Ended March 31, 2023 2022 Weighted-average risk-free interest rate 3.65 % 1.67 % Expected dividend yield — % — % Expected volatility 111 % 105 % Expected terms 6.0 years 6.0 years
Schedule of Nonvested Restricted Stock Units Activity	The following is a summary of restricted stock unit activity under the 2014 Plan and Inducement Plan: Number of Weighted-Average Nonvested at December 31, 2022 201,998 $ 44.47 Granted 339,950 0.67 Vested ( 67,526 ) 55.27 Forfeited ( 4,470 ) 38.99 Nonvested at March 31, 2023 469,952 $ 11.28
Summary of Stock-Based Compensation Expense for Stock Options Granted that was Recorded in the Company's Results of Operations	The following table summarizes the stock-based compensation expense resulting from awards granted under Stock Incentive Plans, the Inducement Plan and the 2014 ESPP, that was recorded in the Company’s results of operations for the periods presented (in thousands): Three Months Ended 2023 2022 Cost of product revenue $ 54 $ 129 Research and development 280 422 Selling, general and administrative 1,462 1,994 Total stock-based compensation expense $ 1,796 $ 2,545

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock or if-converted methods, because their effect would have been anti-dilutive for the periods presented: Three Months Ended 2023 2022 Options to purchase common shares 167,446 198,393 Restricted stock units 469,952 257,867 Term Loan Warrants 21,944 21,944 Series A Warrant 42,857 — Common Stock warrants 19,878,148 — Total 20,580,347 478,204

Nature of Business - Additional

Nature of Business - Additional Information (Detail) - USD ($)

1 Months Ended

Mar. 30, 2023

Nov. 14, 2022

Feb. 28, 2023

Feb. 28, 2022

May 22, 2023

May 19, 2023

Mar. 31, 2023

Feb. 17, 2023

Dec. 31, 2022

Nov. 22, 2022

Mar. 31, 2022

Dec. 31, 2021

Nature Of Business [Line Items]

Cash, cash equivalents and restricted cash

$ 10,700,000

Cash, cash equivalents, marketable securities and restricted cash

10,700,000

Accumulated deficit

552,184,000

$ 534,219,000

Stockholders' deficit

49,886,000

$ 39,655,000

$ 25,651,000

$ 12,903,000

Proceeds from common stock and warrants sale

$ 12,000,000

Minimum market value of listed securities

$ 35,000,000

$ 35,000,000

Common stock, par value (in dollars per share)

$ 0.001

$ 0.001

$ 0.001

Number of extension days to regain compliance

180 days

Subsequent Event [Member]

Nature Of Business [Line Items]

Percentage of workforce reduction

30%

Forecast [Member]

Nature Of Business [Line Items]

Minimum market value of listed securities

$ 35,000,000

Maximum [Member]

Nature Of Business [Line Items]

Common stock, par value (in dollars per share)

$ 1

Minimum [Member]

Nature Of Business [Line Items]

Stock trading price

$ 1

Common stock, par value (in dollars per share)

$ 1

Term Loan Agreement [Member] | CRG [Member]

Nature Of Business [Line Items]

Minimum cash covenant after reduction

$ 5,000,000

Debt maturity date

Dec. 30, 2024

Dec. 30, 2023

Waiver and Consent to Term Loan Agreement [Member] | CRG [Member] | Subsequent Event [Member]

Nature Of Business [Line Items]

Minimum cash covenant after reduction

$ 500,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail) $ in Thousands		3 Months Ended
	Oct. 12, 2022 shares	Mar. 31, 2023 USD ($) Segment	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)
Product Information [Line Items]
Stock split, conversion ratio	0.02
Number of operating segments | Segment		1
Total revenue		$ 2,078	$ 7,234
Outstanding receivable		$ 1,323		$ 2,163
Remaining performance obligation, expected timing of satisfaction		The Company expects to recognize 53% of this amount as revenue within one year and the remainder within three years.
Contract liabilities		$ 200		200
Revenue recognized relating to contract liabilities		100
Other Non-Current Assets [Member]
Product Information [Line Items]
Contract assets		$ 200		100
T2 Dx [Member]
Product Information [Line Items]
Maintenance Services period (in years)		1 year
Additional period for Maintenance Service option (in years)		1 year
Maximum [Member]
Product Information [Line Items]
Original expected period of contracts for which value of unsatisfied performance obligations not to be disclosed		1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period		3 years
Non-US [Member]
Product Information [Line Items]
Total revenue		$ 800	$ 1,000
Outstanding receivable		1,400		$ 400
Italy [Member]
Product Information [Line Items]
Total revenue		$ 400
Revenue [Member] | Geographic Concentration Risk [Member] | Non-US [Member]
Product Information [Line Items]
Total revenue (as a percent)		36%	13%
Revenue [Member] | Geographic Concentration Risk [Member] | Non-US [Member] | Maximum [Member]
Product Information [Line Items]
Total revenue (as a percent)			10%
Revenue [Member] | Geographic Concentration Risk [Member] | Italy [Member]
Product Information [Line Items]
Total revenue (as a percent)		19%
Common Stock [Member]
Product Information [Line Items]
Reverse stock split description		effected a 50 for 1 reverse stock split. One share of common stock was issued for every 50 shares of issued and outstanding
Stock issued during period, shares, stock splits | shares	50

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Customers Represent Greater Than 10% Of Revenue (Details) - Customer Concentration Risk [Member] - Revenue [Member]	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Customer A [Member]
Product Information [Line Items]
Total revenue (as a percent)	20%	47%
Customer B [Member]
Product Information [Line Items]
Total revenue (as a percent)	19%	5%

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Customers Represent Greater Than 10% Of Accounts Receivable (Details) - Customer Concentration Risk [Member] - Accounts Receivable [Member]	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Customer A [Member]
Product Information [Line Items]
Total accounts receivable (as a percent)	0%	32%
Customer B [Member]
Product Information [Line Items]
Total accounts receivable (as a percent)	28%	0%

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Disaggregation of Total Revenue by Major Resource (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation Of Revenue [Line Items]
Total revenue	$ 2,078	$ 7,234
Product Instruments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	322	646
Product Consumables [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	1,177	2,950
Instrument Rentals [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	55	18
Total Product Revenue [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	1,655	3,844
Contribution Revenue [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	423	3,390
Service [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	$ 101	$ 230

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Additional Information 1 (Detail) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2023-04-01 $ in Millions	Mar. 31, 2023 USD ($)
Product Information [Line Items]
Transaction price that is allocated to unsatisfied or partially satisfied performance obligations, that has not yet been recognized as revenue	$ 0.2
Percentage of revenue recognition	53%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Financial Assets and Liabilities at Fair value on a Recurring Basis (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Liabilities:
Warrant liabilities	$ 7,972	$ 39
Derivative liability related to Term Loan	1,858	1,088
Estimate of Fair Value Measurement [Member] | Recurring [Member]
Liabilities:
Warrant liabilities	7,972	39
Derivative liability related to Term Loan	1,858	1,088
Total liabilities	9,830	1,127
Level 2 [Member] | Estimate of Fair Value Measurement [Member] | Recurring [Member]
Liabilities:
Warrant liabilities	16	39
Total liabilities	16	39
Level 3 [Member] | Estimate of Fair Value Measurement [Member] | Recurring [Member]
Liabilities:
Warrant liabilities	7,956
Derivative liability related to Term Loan	1,858	1,088
Total liabilities	$ 9,814	$ 1,088

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares	Dec. 31, 2022 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability, noncurrent	$ 1,858	$ 1,088
Term Loan Agreement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Additional interest rate, event of default (as a percent)	4%
Money Market Accounts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted cash		1,600
Money Market Accounts [Member] | Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted cash	$ 600	$ 600
Common Stock Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Exercise price of warrants | $ / shares	$ 1.08
Common Stock Warrants [Member] | Risk-free Interest Rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants outstanding, measurement input	3.61
Common Stock Warrants [Member] | Expected Volatility [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants outstanding, measurement input	117
Common Stock Warrants [Member] | Expected Volatility [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants outstanding, measurement input	119
Common Stock Warrants [Member] | Expected Dividend Yield [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants outstanding, measurement input	0
Common Stock Warrants [Member] | Share Price [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Stock price | $ / shares	$ 0.54
Common Stock Warrants [Member] | Expected Term [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants outstanding, term	0 years
Common Stock Warrants [Member] | Expected Term [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants outstanding, term	4 years 10 months 17 days

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Estimated Fair Value of the Warrant Liability (Details) - Warrant [Member]	3 Months Ended
	Mar. 31, 2023
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Risk-free interest rate	3.61%
Expected dividend yield	0%
Expected volatility	120%
Expected term	4 years 10 months 17 days

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Roll-forward of Fair Value of Common Stock Warrants (Details) - Common Stock Warrants [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Issuance of Common Stock Warrant	$ 7,568
Settlement due to cashless exercise	(938)
Change in fair value	1,326
Balance at March 31, 2023	$ 7,956

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Contingent Interest Payments (Detail)	3 Months Ended
	Mar. 31, 2023
Contingent Interest Beginning in Q1 2023 [Member] | Measurement Input, Discount Rate [Member] | Term Loan Agreement [Member] | CRG [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
4% contingent interest beginning in Q1 2023, probability	60%

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Contingent Interest Payments (Parenthetical) (Detail)	3 Months Ended
	Mar. 31, 2023
CRG [Member] | Term Loan Agreement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent payment of interest rate	4%

Fair Value Measurements - Roll-

Fair Value Measurements - Roll-Forward of Fair Value of Derivative Liability related to Term Loan (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance at December 31, 2022	$ 1,088
Change in fair value of derivative related to Term Loan	(770)
Balance at March 31, 2023	1,858
Probability Weighted Discounted Cash Flow Model
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in fair value of derivative related to Term Loan	$ 770

Restricted Cash - Additional In

Restricted Cash - Additional Information (Detail) - Money Market Accounts [Member] - USD ($) $ in Millions	Mar. 31, 2023	Jan. 31, 2023	Dec. 31, 2022
Restricted Cash And Cash Equivalents Items [Line Items]
Security deposits			$ 1.6
Landlord [Member]
Restricted Cash And Cash Equivalents Items [Line Items]
Security deposits		$ 1
FDIC [Member]
Restricted Cash And Cash Equivalents Items [Line Items]
Security deposits	$ 0.6

Supplemental Balance Sheet In_3

Supplemental Balance Sheet Information - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Inventory Net [Abstract]
Raw materials	$ 2,571	$ 2,004
Work-in-process	1,674	1,176
Finished goods	691	1,105
Total inventories, net	$ 4,936	$ 4,285

Supplemental Balance Sheet In_4

Supplemental Balance Sheet Information - Schedule of Property and Equipment (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 19,242	$ 18,790
Less accumulated depreciation and amortization	(14,441)	(14,257)
Property and equipment, net	4,801	4,533
Office and Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	757	757
Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	783	783
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	5,594	5,570
Furniture [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	210	197
Manufacturing Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,454	1,454
Manufacturing Tooling and Molds [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	494	494
T2-Owned Instruments and Components [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	4,285	4,052
Leased T2 Owned Instruments [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,011	1,014
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	3,785	3,784
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 869	$ 685

Supplemental Balance Sheet In_5

Supplemental Balance Sheet Information - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Supplemental Balance Sheet Information [Line Items]
Raw materials and work-in-process inventory	$ 1,000		$ 800
Depreciation and amortization	$ 256	$ 286
Office, Research, Laboratory and Manufacturing Space [Member] | Accrued Liabilities [Member]
Supplemental Balance Sheet Information [Line Items]
Estimated liability pertaining to lease			$ 1,000

Supplemental Balance Sheet In_6

Supplemental Balance Sheet Information - Components of Accrued Expenses (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Accrued Liabilities Current [Abstract]
Accrued payroll and compensation	$ 2,270	$ 2,930
Accrued research and development expenses	826	1,097
Accrued professional services	604	1,626
Accrued interest	996	1,009
Operating lease liabilities	1,415	1,352
Other accrued expenses	466	607
Total accrued expenses and other current liabilities	$ 5,162	$ 7,269

Notes Payable - Schedule of Deb

Notes Payable - Schedule of Debt (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Term Loan Agreement including PIK interest, before unamortized discount and issuance costs	$ 53,453	$ 53,453
Less: unaccrued paid-in-kind interest	(3,211)	(3,647)
Less: unamortized discount and deferred issuance costs	(134)	(155)
Total notes payable	$ 50,108	$ 49,651

Notes Payable - Term Loan Agree

Notes Payable - Term Loan Agreement - Additional Information (Detail) - USD ($)			1 Months Ended		3 Months Ended
	May 19, 2023	Nov. 14, 2022	Feb. 28, 2022	Dec. 31, 2016	Mar. 31, 2023	Dec. 31, 2019
Common Stock [Member]
Debt Instrument [Line Items]
Number of warrants outstanding					21,944
Number of shares issuable for warrants outstanding (in shares)				10,579		11,365
Exercise price of warrants				$ 77.50		$ 77.50
Term Loan Agreement [Member]
Debt Instrument [Line Items]
Additional interest rate, event of default (as a percent)					4%
CRG [Member] | Term Loan Agreement [Member]
Debt Instrument [Line Items]
Debt maturity date		Dec. 30, 2024	Dec. 30, 2023
Proceeds from issuance of long-term debt				$ 40,000,000
Debt term (in years)				6 years
Payable in cash quarterly (as a percent)				8%
Final fee as a percentage of the principal outstanding (as a percent)				8%	10%	10%
Annual fixed rate (as a percent)				11.50%
Deferred interest rate (as a percent)				3.50%
Minimum cash balance					$ 5,000,000
CRG [Member] | Waiver and Consent to Term Loan Agreement [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Minimum cash balance	$ 500,000
Minimum liquidity covenant, waiver expiration date	Dec. 31, 2023

Warrants - Additional Informati

Warrants - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions			3 Months Ended
	Feb. 17, 2023	Aug. 15, 2022	Mar. 31, 2023	Mar. 30, 2023	Dec. 31, 2022	Dec. 31, 2019	Dec. 31, 2016
Class Of Warrant Or Right [Line Items]
Number of shares issued/sold	9,018,519
Common stock, par value (in dollars per share)	$ 0.001		$ 0.001		$ 0.001
Total proceeds from offering	$ 12
Issuance costs related to offering	1.1
Other Expenses [Member]
Class Of Warrant Or Right [Line Items]
Issuance costs related to offering	$ 0.7
Maximum [Member]
Class Of Warrant Or Right [Line Items]
Common stock, par value (in dollars per share)				$ 1
Minimum [Member]
Class Of Warrant Or Right [Line Items]
Common stock, par value (in dollars per share)				$ 1
Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Number of shares issuable for warrants outstanding (in shares)						11,365	10,579
Exercise price of warrants						$ 77.50	$ 77.50
Number of warrants outstanding			21,944
Common Share and Common Stock Warrant [Member]
Class Of Warrant Or Right [Line Items]
Share price	$ 1.08
Pre-funded Warrant and Common Stock Warrant [Member]
Class Of Warrant Or Right [Line Items]
Share price	1.079
Series A Warrant [Member] | Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Number of shares issuable for warrants outstanding (in shares)		42,857
Exercise price of warrants	$ 0.54	$ 7.50
Aggregate subscription amount		$ 0.3
Warrants exercisable date		Feb. 15, 2023
Warrants maturity term		Feb. 15, 2028
Fair value of warrant liability		$ 0.4
Series A Warrant [Member] | Common Stock [Member] | Maximum [Member]
Class Of Warrant Or Right [Line Items]
Gain (loss) on change in fair value of warrants			$ 0.1
Pre-funded Warrants [Member]
Class Of Warrant Or Right [Line Items]
Number of shares issuable for warrants outstanding (in shares)	2,092,592
Exercise price of warrants	$ 0.001
Share price			$ 0.001
Procceds allocated to warrants	$ 0.8
Number of warrants exercised			1,740,740
Number of warrants outstanding			351,852
Common Stock Warrants [Member]
Class Of Warrant Or Right [Line Items]
Number of shares issuable for warrants outstanding (in shares)	22,222,222
Exercise price of warrants	$ 1.08
Warrants exercisable date	Mar. 15, 2023
Warrants maturity term	Feb. 17, 2028
Fair value of warrant liability	$ 7.6
Number of warrants exercised			2,344,074
Number of warrants outstanding			19,878,148
Gain (loss) on change in fair value of warrants			$ (1.3)
Common Stock Warrants [Member] | Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Number of shares issuable for warrants outstanding (in shares)			1,172,037
Number of securities called by each warrant	2
Series A Redeemable Convertible Preferred Stock [Member]
Class Of Warrant Or Right [Line Items]
Series A redeemable convertible preferred stock, shares issued		3,000
Series A redeemable convertible preferred stock, par value (in dollars per share)		$ 0.001

Stockholders' Deficit - Additio

Stockholders' Deficit - Additional Information (Detail) $ / shares in Units, $ in Millions			3 Months Ended
	Feb. 17, 2023 $ / shares shares	Mar. 31, 2021 USD ($)	Mar. 31, 2023 USD ($) Item $ / shares shares	Mar. 31, 2022 USD ($) shares	Dec. 31, 2022 $ / shares shares
Class Of Stock [Line Items]
Common stock, shares authorized			400,000,000		400,000,000
Number of shares issued/sold	9,018,519
Preferred stock, shares authorized			10,000,000		10,000,000
Preferred stock, par value (in dollars per share) | $ / shares			$ 0.001		$ 0.001
Common stock, par value (in dollars per share) | $ / shares	$ 0.001		$ 0.001		$ 0.001
Number of voting rights per share of common stock | Item			1
Sales Agreement [Member] | Canaccord [Member]
Class Of Stock [Line Items]
Aggregate gross sales amount of common stock | $		$ 75
Percentage of agent service fee		3%
Number of shares issued/sold			653,122	70,987
Proceeds from issuance of common stock | $			$ 0.9	$ 1.4

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Aug. 06, 2020	Mar. 31, 2018
Share-Based Compensation
Fair value of vested stock options	$ 300,000	$ 600,000
Stock-based compensation expense	$ 1,796,000	2,545,000
Employee Stock Purchase Plan [Member]
Share-Based Compensation
Shares available for grant	22,849
Shares available for authorization			90,478
Percentage of full share price paid in purchase of common stock	85%
Maximum amount of annual employee common stock purchases	$ 25,000
Stock-based compensation expense		100,000
Restricted Stock Units [Member]
Share-Based Compensation
Weighted-average period	1 year 3 months 18 days
Unrecognized compensation cost related to unvested stock options	$ 4,900,000
2014 Stock Option Plan [Member] | Stock Options [Member]
Share-Based Compensation
Shares available for future issuance under stock incentive plan	16,470
Percentage of common shares outstanding	4%
Shares available for grant	93,387
Inducement Award Plan [Member]
Share-Based Compensation
Shares available for grant	52,689
Shares available for authorization				192,500
2006 and 2014 Stock Option Plans [Member] | Stock Options [Member]
Share-Based Compensation
Aggregate fair value of options granted		$ 200,000
Unrecognized compensation cost related to non-vested stock options	$ 1,200,000
Weighted-average period	1 year 7 months 6 days
2006 and 2014 Stock Option Plans and Inducement Plan [Member] | Stock Options [Member]
Share-Based Compensation
Issuance of common stock from exercise of stock options (in shares)	0	0
Weighted average fair value of options granted	$ 1.34	$ 16.57
2006 and 2014 Stock Option Plans and Inducement Plan [Member] | Restricted Stock Units [Member]
Share-Based Compensation
Aggregate fair value of restricted stock units granted	$ 200,000
Maximum [Member] | 2006 Stock Option Plan [Member] | Stock Options [Member]
Share-Based Compensation
Expiration period	10 years
Vesting period	4 years
Maximum [Member] | 2014 Stock Option Plan [Member] | Stock Options [Member]
Share-Based Compensation
Expiration period	10 years
Vesting period	4 years
Issuance of common stock from exercise of stock options (in shares)	700,000

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Detail) - 2006 and 2014 Stock Option Plans and Inducement Plan [Member] - Stock Options [Member] - $ / shares	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Share-Based Compensation
Number of Shares Outstanding, beginning of the period	179,641
Number of Shares, Granted	6,220
Number of Shares, Exercised	0	0
Number of Shares, Forfeited	(3,981)
Number of Shares, Cancelled	(14,434)
Number of Shares Outstanding, end of the period	167,446		179,641
Number of Shares, Exercisable	126,982
Number of Shares, Vested or expected to vest	161,179
Weighted-Average Exercise Price Per Share Outstanding, beginning of the period	$ 145.09
Weighted-Average Exercise Price Per Share, Granted	1.59
Weighted-Average Exercise Price Per Share, Forfeited	21.95
Weighted-Average Exercise Price Per Share, Cancelled	149.80
Weighted-Average Exercise Price Per Share Outstanding, end of the period	142.28		$ 145.09
Weighted-Average Exercise Price Per Share, Exercisable	175.16
Weighted-Average Exercise Price Per Share, Vested or expected to vest	$ 146.59
Weighted-Average Remaining Contractual Term, Outstanding	6 years 2 months 8 days		5 years 11 months 4 days
Weighted-Average Remaining Contractual Term, Exercisable	5 years 6 months 21 days
Weighted-Average Remaining Contractual Term, Vested or expected to vest	6 years 1 month 2 days

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Estimated Assumptions Used to Calculate Weighted-Average Grant Date Fair Value of Options Granted (Detail) - Stock Options [Member] - 2006 and 2014 Stock Option Plans and Inducement Plan [Member]	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-Based Compensation
Weighted-average risk-free interest rate	3.65%	1.67%
Expected volatility	111%	105%
Expected terms	6 years	6 years

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Nonvested Restricted Stock Units Activity (Detail) - 2014 Stock Option Plan and Inducement Plan [Member] - Restricted Stock Units [Member]	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Share-Based Compensation
Number of Shares, Nonvested restricted shares at the beginning of the period | shares	201,998
Number of Shares, Restricted shares granted | shares	339,950
Number of Shares, Restricted shares vested | shares	(67,526)
Number of Shares, Restricted shares forfeited | shares	(4,470)
Number of Shares, Nonvested restricted shares at the end of the period | shares	469,952
Weighted-Average Grant Date Fair Value, Nonvested restricted shares at the beginning of the period | $ / shares	$ 44.47
Weighted-Average Grant Date Fair Value, Granted | $ / shares	0.67
Weighted-Average Grant Date Fair Value, Vested | $ / shares	55.27
Weighted-Average Grant Date Fair Value, Forfeited | $ / shares	38.99
Weighted-Average Grant Date Fair Value, Nonvested restricted shares at the end of the period | $ / shares	$ 11.28

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Stock-Based Compensation Expense for Stock Options Granted that was Recorded in the Company's Results of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Stock-based compensation expense
Stock-based compensation expense	$ 1,796	$ 2,545
Cost of Product Revenue [Member]
Stock-based compensation expense
Stock-based compensation expense	54	129
Research and Development [Member]
Stock-based compensation expense
Stock-based compensation expense	280	422
Selling, General and Administrative [Member]
Stock-based compensation expense
Stock-based compensation expense	$ 1,462	$ 1,994

Net Loss Per Share - Additional

Net Loss Per Share - Additional Information (Detail)	Mar. 31, 2023 $ / shares
Pre-Funded Warrants [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Share price	$ 0.001

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of diluted net loss per share	20,580,347	478,204
Options to Purchase Common Shares [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of diluted net loss per share	167,446	198,393
Restricted Stock Units [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of diluted net loss per share	469,952	257,867
Term Loan Warrants [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of diluted net loss per share	21,944	21,944
Common Stock Warrants [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of diluted net loss per share	19,878,148
Series A Warrants [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of diluted net loss per share	42,857

US Government Contract - Additi

US Government Contract - Additional Information (Detail) - USD ($)	1 Months Ended			3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Sep. 30, 2019
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue				$ 2,078,000	$ 7,234,000
Contribution [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue				423,000	3,390,000
Co Development Partnership Agreement [Member] | Biomedical Advanced Research and Development Authority [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Initial value of consideration receivable							$ 6,000,000
First contract option value exercised			$ 10,500,000
Option contract value exercised		$ 6,400,000
Collaborative arrangement additional funding amount received					4,400,000
Collaborative arrangement additional funding amount to be received	$ 3,700,000
Unbilled accounts receivable				0		$ 700,000
Co Development Partnership Agreement [Member] | Biomedical Advanced Research and Development Authority [Member] | Contribution [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue				$ 400,000	$ 3,400,000
Co Development Partnership Agreement [Member] | Biomedical Advanced Research and Development Authority [Member] | Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Aggregate consideration receivable							$ 62,000,000

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($)

1 Months Ended

3 Months Ended

Sep. 30, 2022

Sep. 30, 2021

Oct. 31, 2020

Aug. 31, 2018

Mar. 31, 2017

Nov. 30, 2014

Mar. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2019

Jan. 31, 2018

Jan. 11, 2011

Leases [Line Items]

Operating lease right-of-use assets

$ 8,420,000

$ 8,741,000

Office Space, Laboratory Space, and Equipment [Member]

Leases [Line Items]

Operating lease right-of-use assets

0

Lease liabilities

$ 0

Maximum lease period to not recognize right of use assets or lease liabilities

12 months

Office Laboratory And Manufacturing Space | Operating Leases Entered Into May 2013 [Member]

Leases [Line Items]

Lease expiration date

Dec. 31, 2024

Dec. 31, 2022

Dec. 31, 2020

Laboratory Space [Member] | Operating Lease Entered into November 2014 [Member]

Leases [Line Items]

Lease expiration date

Oct. 31, 2025

Security deposits

$ 130,977

130,977

$ 281,000

Term of lease

6 years

Space build-out costs paid

$ 1,400,000

Space build-out costs

$ 2,200,000

Security deposit received from landlord

281,000

Office, Research, Laboratory and Manufacturing Space [Member] | Operating Leases Entered Into September 2021 [Member]

Leases [Line Items]

Security deposits

1,000,000

$ 1,000,000

Term of lease

126 months

Office, Research, Laboratory and Manufacturing Space [Member] | Operating Lease Termination [Member]

Leases [Line Items]

Security deposits

1,000,000

Office, Research, Laboratory and Manufacturing Space [Member] | Accrued Liabilities [Member]

Leases [Line Items]

Estimated liability pertaining to lease

1,000,000

Office, Research, Laboratory and Manufacturing Space [Member] | Accrued Liabilities [Member] | Operating Leases Entered Into September 2021 [Member]

Leases [Line Items]

Estimated liability pertaining to lease

1,000,000

Office and Laboratory Space [Member] | Operating Lease Entered into August 2010 [Member]

Leases [Line Items]

Lease expiration date

Dec. 31, 2028

Dec. 31, 2021

Security deposits

$ 420,438

$ 420,438

$ 160,000

$ 400,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended	24 Months Ended
	Sep. 30, 2021	Mar. 31, 2023	Dec. 31, 2007	Mar. 30, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2006
Mr. Sprague, Mr. Giffin, and Mr. Gibbs [Member]
Commitments and Contingencies [Line Items]
Retention bonus payable				$ 80,000
License Agreement [Member]
Commitments and Contingencies [Line Items]
Shares issued			1,693
Royalty on net sales sublicensing gross revenue		10%
License Agreement [Member] | Minimum [Member]
Commitments and Contingencies [Line Items]
Annual license fee payable							$ 5,000
Percentage of royalty on net sales		0.50%
License Agreement [Member] | Maximum [Member]
Commitments and Contingencies [Line Items]
Annual license fee payable							$ 25,000
Percentage of royalty on net sales		3.50%
June 30, 2023 [Member] | Mr. Sprague, Mr. Giffin, and Mr. Gibbs [Member]
Commitments and Contingencies [Line Items]
Retention bonus payable				40,000
November 15, 2023 [Member] | Mr. Sprague, Mr. Giffin, and Mr. Gibbs [Member]
Commitments and Contingencies [Line Items]
Retention bonus payable				$ 40,000
Office, Research, Laboratory and Manufacturing Space [Member] | Accrued Liabilities [Member]
Commitments and Contingencies [Line Items]
Estimated liability pertaining to lease					$ 1,000,000
Operating Leases Entered Into September 2021 [Member] | Office, Research, Laboratory and Manufacturing Space [Member]
Commitments and Contingencies [Line Items]
Term of lease	126 months
Security deposit					1,000,000	$ 1,000,000
Operating Leases Entered Into September 2021 [Member] | Office, Research, Laboratory and Manufacturing Space [Member] | Accrued Liabilities [Member]
Commitments and Contingencies [Line Items]
Estimated liability pertaining to lease					$ 1,000,000
Operating Lease Termination [Member] | Office, Research, Laboratory and Manufacturing Space [Member]
Commitments and Contingencies [Line Items]
Security deposit		$ 1,000,000

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail)	May 19, 2023 USD ($)
CRG [Member] | Waiver and Consent to Term Loan Agreement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Minimum cash covenant after reduction	$ 500,000